Published in final edited form as:

Pharmacol Ther. 2019 February ; 194: 145–160. doi:10.1016/j.pharmthera.2018.10.001.

ENDOTHELINS IN INFLAMMATORY NEUROLOGICAL DISEASES

Pedro D'Orleans-Juste¹, Oscar Bate Akide Ndunge², Louisane Desbiens¹, Herbert B. Tanowitz³, and Mahalia S. Desruisseaux^{2,3,*}

¹Department of Pharmacology. Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, CA

²Department of Medicine. Yale University School of Medicine, New Haven, CT, USA

³Departments of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, NY, USA

Abstract

Endothelins were discovered more than thirty years ago as potent vasoactive compounds. Beyond their well-documented vasomodulatory properties, however, the contributions of the endothelin pathway have been demonstrated in several neuroinflammatory processes and the peptides have been reported as a clinically relevant biomarkers in neurodegenerative diseases. Several published works suggest that endothelin-1 greatly contributes to the progression of neuroinflammatory processes, particularly during infections in the central nervous system (CNS), and is associated with a loss of endothelial integrity at the blood brain barrier level. Because of the paucity of clinical trials with endothelin-1 antagonists in several infectious and non-infectious neuroinflammatory diseases, it remains an open question whether the 21 amino acid peptide is a mediator rather than a biomarker of the progression of neurodegeneration. The present review focuses on the potential roles of endothelins in the pathology of neuroinflammatory processes, including infectious diseases of viral, bacterial or parasitic origin in which the synthesis of endothelins or its pharmacology have been investigated from the cell to the bedside in several cases, and non-infectious inflammatory processes such as neurodegenerative disorders like Alzheimers Disease or central nervous system vasculitis.

Keywords

Endothelin-1 (ET-1); cytokines; central nervous system; blood-brain barrier (BBB); chymase; mast cells; endothelin subtype B receptor (ET_B); endothelin subtype A receptor (ET_A); cerebral blood flow (CBF)

---

*Corresponding author at: Associate Professor of Medicine, Section of Infectious Diseases, Yale University School of Medicine PO Box 208022, TAC S169B New Haven, CT 06520-8022. mahalia.desruisseaux@yale.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest Statement

The authors declare that there are no conflicts of interest

INTRODUCTION

In the central nervous system (CNS), the response to adverse events such as infection and the development disorders is accompanied by an upregulation of the inflammatory response and alterations in the vasculature. In this regard, the endothelins have been demonstrated to mediate these responses (Figure 1). The endothelin (ET) family is comprised of three isoforms of 21-amino acid cyclic vasoactive peptides (ET-1, ET-2 and ET-3). A fourth isoform (ET-4) has been reported in the rat and mouse as the analogue to human ET-2 (Cunningham ME, *et al.*, 1997; Khimji & Rockey, 2010; Motte, *et al.*, 2006; Yanagisawa M, *et al.*, 1988). ETs are synthesized from inactive precursor pro-polypeptides. The first product of the ET-1 gene is Pre-proendothelin, a peptide constituted of 212 amino acids. This peptide is processed by a carboxypeptidase to form proendothelin. Furin, an enzyme of the subtilisin family cleaves the proendothelin further to generate Big ET-1 (Blais, *et al.*, 2002; D'Orleans-Juste, *et al.*, 2003). The endothelin converting enzyme (ECE) then cleaves the bond between Trp²¹ and Val²² of Big ET-1 to generate ET-1 [Figure 1; (D'Orleans-Juste, *et al.*, 2003; McMahon, *et al.*, 1991)]. ECE is a zinc-dependent metalloendopeptidase localized in several cell types such as endothelial cells, smooth muscle cells, cardiomyocytes and macrophages (Barnes & Turner, 1997, 1999; Hioki, *et al.*, 1991; Hisaki, *et al.*, 1993; Korth, *et al.*, 1999; Takahashi M, *et al.*, 1995).

The membrane bound-ECE family is comprised of the ECE-1, ECE-2 and ECE-3 isoforms with the former two moieties subdivided in functional isoforms (Emoto & Yanagisawa, 1995; Hasegawa, *et al.*, 1998; Shimada, *et al.*, 1994; Xu, *et al.*, 1994). These sub-isoforms possess different N-terminal endings, are differently localized within the cell and preferably hydrolyze the ET-1 precursor Big-ET-1 (D'Orleans-Juste, *et al.*, 2003).

The ECE-dependent pathway is not the sole pathway leading to the formation of ET-1. In embryos of mice whose ECE-1 and ECE-2 genes were knocked out, the production of ET-1 is only decreased by 33% (Yanagisawa H, *et al.*, 2000). This suggests that other pathways involved in the production of ET-1 exist, independently of the canonical endothelin converting enzymes. One of those alternate pathways involves the contribution of mast cell-derived chymase. This serine protease matures Big ET-1 to ET-1. Chymase cleaves the 38-amino acid precursor Big ET-1 at the Tyr³¹-Gly³² bond leading to the formation of an intermediate 31-amino acid peptide, ET-1 (1–31). ET-1 (1–31) is further processed by the Neutral Endopeptidase, which hydrolyzes the Trp²¹-Val²² bond to form ET-1 *in vitro* (Hanson, *et al.*, 1997; Nakano, *et al.*, 1997) and *in vivo* (Fecteau, *et al.*, 2005) (Figure 1).

The three human ET isoforms bind to two seven transmembrane G-protein-coupled cell surface receptors commonly known as ET receptor subtype A (ET_A) and subtype B (ET_B) (Arai, *et al.*, 1990). ET-1 binds to ET_A with the highest affinity compared to ET-2 and ET-3. On the other hand, all of the ET isoforms show equal binding affinity for ET_B (Masaki, 2004; Rubanyi & Polokoff, 1994; Sakurai, *et al.*, 1990). ET-1 is by far the most abundant and best described isoform (Struck, *et al.*, 2005).

Some of the important functions of ET-1 include eliciting vasoconstriction and vasodilatation via release of nitric oxide (NO), ET clearance, salt balance and water

homeostasis, inflammation, cell proliferation and extracellular matrix production (Bouallegue, *et al.*, 2007; Khimji & Rockey, 2010; Kohan, *et al.*, 2011; Speciale, *et al.*, 1998; Wallace, *et al.*, 1989). ET-1 is synthesized by a variety of cells, including endothelial cells, macrophages, cardiomyocytes, astrocytes, microglia and neuronal cells (D'Haeseleer, *et al.*, 2013; Ehrenreich, *et al.*, 1992; Kedzierski & Yanagisawa, 2001; Kuwaki, *et al.*, 1999; Miller, *et al.*, 1996; Naidoo, Naidoo, Mahabeer, *et al.*, 2004; Naidoo, Naidoo, & Raidoo, 2004; Yanagisawa M, *et al.*, 1988). The plasma concentration of ET is usually low, approximately 0.2–5 pg/mL, with a short blood circulating half-life of 4–7 minutes (Kedzierski & Yanagisawa, 2001).

ET-1: The vascular tone regulator

Although big ET-1, which has some vasoconstrictive properties, is found in the peripheral circulation, ET-1 has a 140-times higher vasoconstrictive potency (Rubanyi & Polokoff, 1994). ET-1 activation of ET_A receptors mediates vasoconstriction through activation of phospholipase C, leading to the formation of inositol triphosphate (IP₃), inducing the release of Ca²⁺ from the endoplasmic reticulum stores. Increased cytosolic Ca²⁺ concentrations result in contraction of the vascular smooth muscle cells (Bouallegue, *et al.*, 2007; Khimji & Rockey, 2010; Wagner, *et al.*, 1992). Conversely, the binding of ET-1 to ET_B receptors mostly mediates vasodilation through activation of the PI3/Akt pathway, with ensuing activation of endothelial NO synthase, generating NO to cause relaxation of the vascular smooth muscle cells. Activation of ET_B receptors present on vascular smooth muscle cells elicits vessel contraction (Khimji & Rockey, 2010; Tsukahara, *et al.*, 1994). Therefore, ET-1 acts as a local modulator of vascular tone. As such, ET-1 plays significant roles in controlling vascular tone by acting directly or indirectly on vascular smooth muscle cells under normal homeostatic (non-disease) state. However, there are some suggestions that enhanced ET-1 secretion might be involved in the pathophysiology of many vascular diseases (Feldstein & Romero, 2007; Iglarz & Clozel, 2007; Marasciulo, *et al.*, 2006).

ET-1: The inflammatory mediator

Initially regarded solely as a spasmogen, ET-1 is now also recognized as a pro-inflammatory cytokine (Sessa, *et al.*, 1991; Teder & Noble, 2000). Production and secretion of ET-1 in endothelial cells are significantly higher during stress to the endothelium, and after exposure to inflammatory cytokines and reactive oxygen species (Kedzierski & Yanagisawa, 2001). ET-1 is also abundant in macrophages, leukocytes and fibroblasts (Gu, *et al.*, 1991; Sessa, *et al.*, 1991), indicating that ET-1 is closely associated with the inflammatory process. In this regard, several investigators have reported that ET-1 stimulates production of the chemokine (C-X-C motif) ligand 8 (CXCL-8) and (C-C motif) ligand 2 (CCL2) in monocytes and mesangial cells, which are known chemoattractants for neutrophils and monocytes (Helset, *et al.*, 1994; Ishizawa, *et al.*, 2004), suggesting that ET-1 contributes to leukocyte activation and trafficking. Moreover, ET-1 also acts as a mast cell activator, inducing degranulation and release of inflammatory cytokines from mast cells (Matsushima, *et al.*, 2004). Interestingly, investigators have shown that ET-1 is also important in inducing traversal of inflammatory cells through endothelial cells into different tissues. shRNA knockdown of ET-1, the ET_B receptor, and ECE-1 demonstrate that these components are independently involved in monocyte diapedesis (Reijerkerk, *et al.*, 2012). In addition, ET-1 induces the upregulation of

cellular adhesion molecules, such as Intercellular cell adhesion molecule 1 (ICAM-1), Vascular cell adhesion protein 1 (VCAM-1), and e-selectin in human brain microvascular endothelial cells, facilitating margination, adherence, and infiltration of leukocytes across these cells into injured tissue (McCarron, *et al.*, 1993). Furthermore, ET-1 causes platelet aggregation, and plays a role in the increased expression of leukocyte adhesion molecules and their synthesis of inflammatory mediators, thus contributing to vascular dysfunction (Matsuo, *et al.*, 2001; Teder & Noble, 2000).

ET-1 is produced at significantly higher rates during a variety of infections (Dai, *et al.*, 2012; Dietmann, *et al.*, 2008; Koedel, *et al.*, 1997; Machado, *et al.*, 2006; Martins, *et al.*, 2016; Petkova, *et al.*, 2000; Petkova, *et al.*, 2001; Wanecek, *et al.*, 2000). In fact, ET-1 has been shown to contribute to the pathogenesis and severity of bacterial, viral and parasitic disease processes including sepsis, meningitis, pneumonia, rickettsial infections, Chagas disease and cerebral malaria (Dai, *et al.*, 2012; Davi, *et al.*, 1995; Freeman, *et al.*, 2016; Goto, *et al.*, 2012; Koedel, *et al.*, 1997; Martins, *et al.*, 2016; Petkova, *et al.*, 2000; Petkova, *et al.*, 2001; Samransamruajkit, *et al.*, 2002; Schuetz, *et al.*, 2008; Tschaikowsky, *et al.*, 2000; Wanecek, *et al.*, 2000; Wenisch, *et al.*, 1996).

ET-1 in the Brain

In the brain, ET-1 is synthesized by vascular endothelial cells as well as by a variety of other cells including neurons and astrocytes (Kedzierski & Yanagisawa, 2001; Schinelli, 2002). The components of this pathway are found throughout the brain suggesting a variety of potential functions. The receptors (ET_A, ET_B) as well as ET-1 and ET-3 are expressed by vascular, neuronal, and glial cells. ET immunoreactivity is present in neurons of the cerebral cortex, striatum, amygdala, hippocampus, paraventricular and supraoptic nuclei of the hypothalamus, subfornical organ, median eminence, raphe nuclei, and pituitary gland (Giaid, *et al.*, 1991; Lee, *et al.*, 1990; Takahashi K, *et al.*, 1991).

ET-1 is the predominant neural ET, but ET-3 predominates in the pituitary gland (Matsumoto, *et al.*, 1989; Yoshizawa, *et al.*, 1990). The ET_A receptor is found on various neurons (Yamada & Kurokawa, 1998). ET_B is localized to the neurons of the diagonal band of Broca, the fibers of the organum vasculosum of the lamina terminalis, the fibers of the median eminence, and the thick fibers of hypothalamic neurons (Yamamoto & Uemura, 1998), which are also luteinizing hormone-releasing hormone-rich. ECE-1 and ECE-2 are also found in the brain. Recent evidence suggests that the ET_A receptor mediates signal transduction in the brain. Intraventricular injection of ET-1 in rats results in behavioral changes, including barrel rolling, body tilting, nystagmus, clonus, and tail extension. Most of these effects occur at doses that do not cause any changes in cerebral blood flow (CBF) (Chew, *et al.*, 1995). Injection of ET-1 into the periaqueductal gray matter reduces pain responses in mice subjected to the hot plate paradigm in a dose-dependent manner (D'Amico, *et al.*, 1996). These data indicate that ET-1 has a role in neurotransmission that is important for an animal's proprioception. In addition, ET-1 exacerbates apoptosis and neuronal cell death in ischemic models (Giuliani, *et al.*, 2007; Leung, *et al.*, 2004). In this regard, endothelin both enhances glutamate-induced neuronal toxicity and reduces clearance

of glutamate by inducing a down regulation of glutamate transporters in astrocytes thereby, intensifying ischemic brain damage (Kobayashi, *et al.*, 2005; Matsuura, *et al.*, 2002).

ET-1 secreted under normal physiological conditions is beneficial in promoting cell proliferation. However, pathologically increased secretion of ET-1 from reactive astrocytes, microglia and neuronal cells in response to endothelial stress, triggered by irritants from drugs, cytokines, chemokines, reactive oxygen species and infections, may be harmful and potentially detrimental to hosts (Kedzierski & Yanagisawa, 2001). It has been demonstrated in both animal models and human patients that elevated levels of ET-1 in blood or tissue subserve pathological roles of ET-1 (Dietmann, *et al.*, 2008; McCarron, *et al.*, 1993; Rolinski, *et al.*, 1999). Furthermore, ET-1 exerts numerous effects on the immune system leading to neuroinflammation. For example, increased ET-1 production has been observed in various autoimmune diseases such as rheumatoid arthritis, giant cell arteritis, and Kawasaki disease (Miyasaka, *et al.*, 1992). Interestingly, plasma levels of ET-1 are increased in Multiple Sclerosis (D'Haeseleer, *et al.*, 2013; Haufschild, *et al.*, 2001); HIV (Chauhan, *et al.*, 2007; Ehrenreich, *et al.*, 1993; Hebert, *et al.*, 2004); Herpesvirus (Bagnato, *et al.*, 2001; Rosano, *et al.*, 2003) and other diseases which affect the brain. We will herein attempt to summarize the contributions of ET-1 and components of the ET system in the pathogenesis of diseases of the central nervous system.

ROLE OF ET-1 IN CNS INFECTIONS

Bacterial toxins act on macrophages to synthesize pro-inflammatory cytokines. These cytokines mediate the production of ET-1 from various sources, including brain microvascular endothelial cells (Figueras-Aloy, *et al.*, 2003; Figueras-Aloy, *et al.*, 2004; McCarron, *et al.*, 1993; Piechota, *et al.*, 2007; Tschakowsky, *et al.*, 2000; Weitzberg, *et al.*, 1991). For instance, during bacterial meningitis, organisms traverse the blood-brain barrier (BBB) into the brain parenchyma by a number of mechanisms (Kim, 2010). Once in the brain, bacteria and bacterial factors activate glia which increase their production and secretion of inflammatory cytokines, prompting activation of endothelial cells, an upregulation in cellular adhesion molecules and the margination of immune cells in the brain microvasculature (Saez-Llorens & McCracken, 2003). Infiltrating leukocytes secrete a variety of proteolytic products and toxins which damage the integrity of the endothelium. During these pathological processes, upregulated ET-1 causes further loss of endothelial integrity and increased BBB permeability, activates astrocytes, induces abnormal expression and production of cellular adhesion molecules including ICAM-1, VCAM-1, and e-selectin, enhanced production of chemoattractants by endothelial cells, besides acting as a neurotransmitter (Ehrenreich, *et al.*, 1990; Hofman, *et al.*, 1998; Koyama, *et al.*, 2007; Koyama, *et al.*, 2013; McCarron, *et al.*, 1993; Miller, *et al.*, 1996; Narushima, *et al.*, 2003; Schwarting, *et al.*, 1996; Wang, *et al.*, 2013; Zidovetzki, *et al.*, 1999). Adhesion molecules are then able to continue the cycle, inducing margination and binding of leukocytes to areas of injury.

Bacterial infections

Bacterial Meningitis—Despite appropriate antimicrobial strategies, adjunctive corticosteroids and supportive therapy, bacterial meningitis continues to be associated with high mortality and persistent residual neurological deficits, including stroke and paralysis (Grimwood, *et al.*, 1995; Grimwood, *et al.*, 2000; Kim, 2010; Merkelbach, *et al.*, 2000; Sellner, *et al.*, 2010). Meningitis is characterized by inflammation of meninges, usually by hematogenous spread following bloodstream infection or by direct extension of infectious organisms from contiguous foci (Chavez-Bueno & McCracken, 2005; Saez-Llorens & McCracken, 2003). An important role for ET-1 in the pathogenesis of bacterial meningitides has been described using animal models of *Streptococcus pneumoniae* infection (Koedel, *et al.*, 1998). Koedel and colleagues have demonstrated that after infection with *S. pneumoniae*, Wistar rats develop cerebrospinal fluid pleocytosis as well as an increase in intracranial pressure, brain water content and CBF (Koedel, *et al.*, 1998). Pre-treatment of the animals with a selective ET_B receptor antagonist, BQ-788, abrogated these abnormalities (Koedel, *et al.*, 1998), suggesting that ET-1 is important in the pathological presentation of bacterial meningitis. Leib *et al.* demonstrated that infant rats with *S. pneumoniae* meningitis exhibited extensive damage in the cortex and dentate gyrus (Leib, *et al.*, 1996), likely induced by ET-1. When infected rats were treated with the non-selective (or dual) ET_A/ET_B receptor antagonist, bosentan, the cortical brain injury was mitigated and CBF was restored to levels comparable to that of uninfected controls (Pfister, *et al.*, 2000).

Several groups have examined possible cellular mechanisms for the etiologic role of ET-1 in the pathogenesis of bacterial meningitis and the induction of host responses during the disease. ET-1 levels in the cerebrospinal fluid are increased in both patients with bacterial meningitis and in experimental models of the disease as a result of increased production in several cell types that make up the neurovascular unit (Koedel, *et al.*, 1997; Koedel, *et al.*, 1998). Astrocytes have been suggested as a possible source of this increase in ET-1 secretion. Using an *in vitro* model of rat astrocytes infected with *S. pneumoniae*, investigators showed significant increases in astrocytic production of ET-1 (Koedel, *et al.*, 1997). Treatment of cells with the ECE inhibitor phosphoramidon prevented the increase in ET-1 (Koedel, *et al.*, 1997). Brain microvascular endothelial cells also contribute to the increase in ET-1 during bacterial meningitis, as *S. pneumoniae* infected brain endothelial cells exhibited an increase in both NO and ET-1 upon activation of ET_B receptors (Koedel, *et al.*, 1998). ET-1 is also likely to be critical in the trafficking of immune cells into the brain during bacterial meningitis. ET-1 and its components have been shown to induce monocyte diapedesis across the (Reijerkerk, *et al.*, 2012). In this regard, ET-1 has been shown to induce the production of potent chemoattractants by endothelial cells, such as CCL2 and CXCL-8, which are significantly elevated in bacterial meningitis (Chen P, *et al.*, 2001; Hofman, *et al.*, 1998; Koyama, *et al.*, 2007; Koyama, *et al.*, 2013; Sprenger, *et al.*, 1996; Zidovetzki, *et al.*, 1999).

ET-1 plays a critical role in generating the host response during bacterial meningitis, causing cerebral vascular and CNS injuries. These abnormalities are likely mediated, in part, by increased ET-1 production in endothelial cells (Koedel, *et al.*, 1997; Koedel, *et al.*, 1998). There are still several gaps in our understanding of the precise processes involved in

inducing leukocyte infiltration to the CNS, and these areas would benefit from further investigations.

Parasitic infections

ET-1 and malaria.—Malaria is a potentially life-threatening disease which affects approximately 216 million individuals and results in more than 400,000 deaths yearly (World Health Organization, 2017). Cerebral malaria (CM) is the most severe and potentially fatal neurological complication with *Plasmodium* infection (Hunt & Grau, 2003; Newton & Krishna, 1998), and children younger than 5 years-old are the most susceptible, accounting for > 70% of the malaria-related deaths (Birbeck, *et al.*, 2010; Carter, *et al.*, 2006; Idro, *et al.*, 2010; World Health Organization, 2014). Despite significant advances in the reduction of global transmission of malaria since 2000 (World Health Organization, 2017), CM continues to have a mortality rate of 20%, and, more than 25% of the survivors develop long-term neurological deficits (Birbeck, *et al.*, 2010; Carter, *et al.*, 2006; Idro, *et al.*, 2010; World Health Organization, 2014), creating enormous social and economic burdens in malaria-endemic regions (Onwujekwe, *et al.*, 2000; World Health Organization, 2014).

Characterized by adherence of parasitized red blood cells to the brain microvasculature, vasospasms, and changes in levels of vasoregulatory molecules, hypoperfusion and ischemia, inflammation and impairment of the BBB (Adams S, *et al.*, 2002; Cabrales, *et al.*, 2010; Dai, *et al.*, 2010; Desruisseaux, *et al.*, 2008; Dorovini-Zis, *et al.*, 2011; Grab, *et al.*, 2011; Kennan, *et al.*, 2005; Potchen, *et al.*, 2010; Renia, *et al.*, 2012), one could certainly deduce that ET-1 contributes to the pathogenesis of CM. Investigators have long demonstrated that plasma levels of ET-1 and big ET-1 are elevated in patients with *P. falciparum* infection in association with damage to the cerebral endothelium (Dietmann, *et al.*, 2008; Wensch, *et al.*, 1996). The elevated levels of ET-1 and of components of the ET system, i.e. ECE, ET_A and ET_B have been tied to glial activation, a reduction in CBF and in damage to neuronal axons in animal models of experimental CM (Kennan, *et al.*, 2005; Machado, *et al.*, 2006).

Recent studies from the Desruisseaux laboratory, employing experimental models of CM demonstrate that ET-1 is critical in inducing the pathological sequelae of the disease (Dai, *et al.*, 2012; Freeman, *et al.*, 2016; Martins, *et al.*, 2016). In mice infected with a non-neurotropic strain of *Plasmodium berghei*, which causes malaria in rodents, Martins *et al.* demonstrated that daily injections of ET-1 induced a CM-like phenotype in the mice, with decreased CBF, increased infiltration of inflammatory cells to cerebral vessels, leakage of the BBB, behavioral changes, and accelerated mortality (Martins, *et al.*, 2016). Other investigators from our group have demonstrated that treatment of mice infected with a neurotropic strain of *P. berghei*, with a selective ET_A receptor antagonist decreased the incidence of brain hemorrhages, improved survival, and prevented malaria-associated cognitive decline, with or without concomitant use of an anti-malarial artemisinin derivative (Dai, *et al.*, 2012; Freeman, *et al.*, 2016). The protective effects of the ET_A receptor blocker were shown to result from mitigation of CM-associated cerebral vasculopathy. ET_A antagonism prevented vasospasms, led to a decrease in leukocyte infiltration of the cerebral

vasculature, likely as a result of decreased production of chemokines and cellular adhesion molecules, and resulted in decreased secretion of circulating inflammatory cytokines (Freeman, *et al.*, 2016)

As with humans, experimental models of CM demonstrate persistent cognitive deficits and impairment of motor coordination, even after antimalarial treatment (Dai, *et al.*, 2010; Desruisseaux, *et al.*, 2008; Lackner, *et al.*, 2006). Treatment with an ET_A receptor antagonist prevented the long-term neurological sequelae in mice with experimental CM (Freeman, *et al.*, 2016). Treatment also improved the survival of affected mice (Dai, *et al.*, 2012; Freeman, *et al.*, 2016).

Although the present data indicate that ET-1 is involved in the pathogenesis of cerebral malaria, studies to determine the precise cells responsible for the increased levels of ET-1 and targets of ET-1 actions during CM are needed.

ET-1 and Chagas Disease—Chagas disease is a neglected tropical disease caused by the protozoan parasite, *Trypanosoma cruzi*, and is a major cause of morbidity and mortality in endemic areas of Latin America and among immigrants to non-endemic areas (Bern & Montgomery, 2009; Roca, *et al.*, 2011; Salvador, *et al.*, 2013; Tanowitz, *et al.*, 2011). The most important manifestations of Chagas disease are cardiomyopathy and the megasyndromes involving the gastrointestinal tract (Tanowitz, *et al.*, 1992). Infection with *T. cruzi* results in an upregulation of pro-inflammatory cytokines, chemokines, Toll-like receptors, components of the mitogen-activated protein kinase pathway, ET-1 and thromboxane A₂ (Ashton, *et al.*, 2007; Petkova, *et al.*, 2001; Tanowitz, *et al.*, 1990). Using selective deletion of the ET-1 gene in endothelial cells and in cardiomyocytes, Tanowitz *et al.* have shown that ET-1 is pivotal to the development of fibrosis and remodeling of the cardiomyocytes during infection (Tanowitz, *et al.*, 2005).

CNS involvement in Chagas disease, however, while recognized since the discovery of *T. cruzi* more than a century ago (Carod-Artal & Gascon, 2010; Carod-Artal, 2013; Chagas, 1911, 1913; Pittella, 2009; Vianna, 1911), has been greatly understudied (Masocha & Kristensson, 2012); as the majority of research has been focused on the cardiomyopathic aspects. Nevertheless, Chagas disease is clearly associated with significant CNS disease. Intracellular *T. cruzi* in the amastigote stage have been reported in brain tissue in autopsy specimens; within CNS monocytic cells and glial cells (Chagas, 1911, 1913; De Queiroz, 1973; Mortara, *et al.*, 1999; Pittella, 2009; Torres & Villaça, 1919; Vianna, 1911) as well as free organisms within inflammatory foci (De Queiroz, 1973). Intracellular replicating parasites within glial cells have been observed in animal models during acute disease, and parasites have also been observed within neurons (Ben Younes-Chennoufi, *et al.*, 1988; Buckner, *et al.*, 1999; Caradonna & Pereiraperrin, 2009).

In 1913, Carlos Chagas described an encephalopathy dubbed “forma nervosa” in over 200 individuals with Chagas disease (Chagas, 1913; Koberle, 1968). Since then, investigations increasingly point toward cerebral microvascular and CNS-derived etiologies in the pathogenesis of neuro-Chagas disease (Mangone, *et al.*, 1994; Nisimura, *et al.*, 2014; Pentreath, 1995). It has been reported that CNS microvasculature is disrupted in Chagas

disease (Carod-Artal, *et al.*, 2011; Nisimura, *et al.*, 2014; Prado, *et al.*, 2011; Tanowitz, *et al.*, 1996); *T. cruzi* infection in mice results in a vasculitis associated with increased cerebral oxidative stress and an increase in leukocyte rolling/adhesion and arteriolar endothelial dysfunction (Nisimura, *et al.*, 2014). The presence of small vessel disease, in several vascular beds in the CNS, is often an underlying etiology of stroke syndromes in Chagasic patients, suggesting an association with microcirculatory alterations (Carod-Artal, *et al.*; Prado, *et al.*, 2011; Tanowitz, *et al.*, 1996). Both acute and chronic CNS infection with *T. cruzi* are marked by lymphocyte infiltration (Britto-Costa, 1971; Pentreath, 1995; Silva AA, *et al.*, 1999). Additionally, population studies and experimental models demonstrate brain atrophy and loss of neurons in several regions of the CNS during Chagas disease, including cortex, cerebellum and hypothalamus (Alencar A., 1964; Brandao & Zulian, 1966; Britto-Costa, 1971; Chuenkova & Pereiraperrin, 2011; Oliveira-Filho, *et al.*, 2009). These pathological changes result in diverse manifestations of acute Chagasic CNS disease which include meningoencephalitis, which can be fatal if left untreated, (Alencar A & Elejalde, 1960; Bern, *et al.*, 2011; Diazgranados, *et al.*, 2009; Pittella, 2009; Py, 2011; Rassi, *et al.*, 2012; Silva N, *et al.*, 1999), and microcephaly and subependymal hemorrhage similar to TORCH syndromes (Bittencourt, 1976; Flores-Chavez, *et al.*, 2008; Mendoza Ticona, *et al.*, 2005).

ET-1 has been shown to contribute to the development of Chagasic cardiomyopathy (Tanowitz, *et al.*, 2005). However, the modulations of ET-1 and its downstream effectors on virulence of the parasite with regard to entry into the CNS, inflammation, and glial and neuronal dysfunction have yet to be explored in CNS Chagas disease.

Viral infections

Past and recent studies in virus-mediated infections, have demonstrated that viral-induced inflammatory reactions of the CNS, triggers activation of neurons, astrocytes and microglia cells in the brain, resulting in the pathogenesis and processes of neurodegenerative diseases (Karim, *et al.*, 2014; Zhou, *et al.*, 2013). A wide range of viruses have been shown to be associated with different types of neurodegenerative diseases by inducing widespread neuronal dysfunctions and degenerations with devastating effects (Hou, *et al.*, 2016; Koyuncu, *et al.*, 2013; McGavern & Kang, 2011). Once in the host, viral infection of the CNS can induce activation of both innate and adaptive immune response (Rivest, 2009). Activated microglial, monocytic, neuronal and astrocytic cells release pro-inflammatory cytokines (endothelins, TNF-alpha, IL-1), chemokine (CCL2 and CCL5 and reactive oxygen species, which mediate the neuroinflammation-induced neurodegenerative diseases (Das Sarma, 2014; Perry VH & Teeling, 2013; Ransohoff & Perry, 2009; Ransohoff & Brown, 2012; Varvel, *et al.*, 2016). Activation of microglia and neuroinflammation may also result in the break-down of the BBB and corresponding leakage of complement into the CNS, chronic neuroinflammation and neurodegenerative disease (Orsini, *et al.*, 2014; Strazza, *et al.*, 2011; Xanthos & Sandkuhler, 2014).

HIV and HIV-associated neurocognitive disorders (HAND)—It has been demonstrated that the human immunodeficiency virus (HIV) causes neurodegeneration by disrupting the BBB, infiltrating the brain, infecting circulatory peripheral blood monocytic

cells which then also migrate into the CNS (Miner & Diamond, 2016), resulting in a chronic neuroinflammatory disease and HIV-associated neurocognitive disorder (HAND) (Malik & Eugenin, 2016; Zayyad Spudich, 2015). HIV-1 and HAND continue to be a major concern in the infected population, despite the use of anti-retrovirals (Carroll & Brew, 2017; Heaton, *et al.*, 2011; Tan & McArthur, 2012).

Abnormally elevated release of the vasoactive mediator ET-1 from activated monocytes, which persists despite anti-retroviral therapy, has been linked to HIV progression, mortality, and HIV-associated cardiovascular and neurocognitive disorders (Didier, *et al.*, 2002; Ehrenreich, *et al.*, 1993). Enhanced ET-1 secretion due to HIV infection induces endothelial damage and dysfunction and has been associated with cardiovascular and other HIV-associated comorbidities (Fitzpatrick, *et al.*, 2016), including HAND (Didier, *et al.*, 2002; Ehrenreich, *et al.*, 1993). HAND is characterized by cognitive, motor, and behavioral abnormalities (Ances & Ellis, 2007; Antinori, Arendt, *et al.*, 2007; Antinori, Trotta, *et al.*, 2007; Gonzalez-Perez, *et al.*, 2017; Kaul, *et al.*, 2005; Letendre, 2011; McArthur, 2004; Sacktor, *et al.*, 2001; Sacktor, 2002). Despite recent advances in antiretroviral therapy and in understanding of the pathogenesis of HIV, and its associated neuronal effects, the mechanisms by which HIV infection causes endothelial dysfunction and subsequent development of HAND remains poorly defined (Ances & Ellis, 2007). Early work by Lane and colleagues and by Fauci demonstrated that the HIV virus transmigrates into the CNS through infected monocytes which infiltrate the BBB (Fauci, 1996; Lane, *et al.*, 1996). It has been demonstrated that once these HIV-infected monocytes/macrophages from the bloodstream have crossed the BBB into the CNS, the virus can then further infect microglia and brain monocytic/macrophagic cells (Boven, *et al.*, 2000; Dallasta, *et al.*, 1999; Trillo-Pazos, *et al.*, 2003). The activated HIV-infected glial cells, including astrocytes, microglia and monocytes/macrophages secrete high levels of ET-1, and other neurotoxic inflammatory mediators, including cytokines (TNF-alpha, IL-1, IL-6), platelet activating factor, and nitric oxide, all of which can cause neuronal injury (Chauhan, *et al.*, 2007; Didier, *et al.*, 2002; Didier, *et al.*, 2003; Ehrenreich, *et al.*, 1993; Kaul, *et al.*, 2001; Swindells, *et al.*, 1999). In addition, viral products, especially the HIV proteins gp120, Tat, Nef, and Rev have been shown to be both neurotoxic and cytotoxic to endothelial cells (Bennett, *et al.*, 1995; Dreyer, *et al.*, 1990; Huang MB, *et al.*, 1999; Kanmogne, *et al.*, 2001; Kaul, *et al.*, 2001; Lannuzel, *et al.*, 1995; Magnuson, *et al.*, 1995; Patel, *et al.*, 2000; Scutari, *et al.*, 2017), and contribute to key processes in HAND through increased vasoconstriction, ET-1 secretion and neuroinflammation (Ramesh, *et al.*, 2013; Rolinski, *et al.*, 1999). The HIV envelope glycoprotein gp120 stimulates macrophages and pulmonary arterial endothelial cells to secrete ET-1 (Didier, *et al.*, 2002; Ehrenreich, *et al.*, 1993; Kanmogne, *et al.*, 2005), which is critical in monocyte diapedesis across the BBB (Hong & Banks, 2015; Scutari, *et al.*, 2017). Cerebral macrophages in patients with HIV encephalopathy strongly express ET-1 (Avalos, *et al.*, 2017; Cotter, *et al.*, 2002; Ehrenreich, *et al.*, 1993). Elevated ET-1 secretion has been linked to neuroinflammation and neuronal damage during HIV (Chauhan, *et al.*, 2007; Rolinski, *et al.*, 1999), but there has been no assessment of the role of ET-1 in the development of HAND.

Increased levels of ET-1 in the cerebrospinal fluid of patients with HIV encephalopathy has been observed in association with neuronal injury, neuroinflammation, increased BBB

leakage and edema, and neurological deficits (Rolinski, *et al.*, 1999; Scutari, *et al.*, 2017; Zhang X, *et al.*, 2013). In addition, *in vitro* studies demonstrate that ET-1 is secreted in a human BBB model of astrocytes and brain microvascular endothelial cells exposed to HIV (Didier, *et al.*, 2002). Furthermore, ET-1 has been shown to act as a chemoattractant for monocytes in the brain via associated increases in the secretion of MCP-1 and IL-8 (Helset, *et al.*, 1994; Ishizawa, *et al.*, 2004), properties which suggest a potential role for ET-1 in the development of HAND. In this regard, ET-1 likely contributes to the increased activation of macrophages and microglia in the CNS which have been shown to play a role in the development of HAND (Chauhan, *et al.*, 2007; Ishikawa, *et al.*, 1997; Lake, *et al.*, 2017; Ma, *et al.*, 1994; Perry VH & Teeling, 2013; Werner & Engelhard, 2007).

Herpes viruses—Herpes viruses are neurotropic pathogens that infect mostly humans (Deigendesch & Stenzel, 2017; Munawwar & Singh, 2016; Swanson & McGavern, 2015). Currently, there are nine (9) herpesvirus types known to infect humans: herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus, Epstein–Barr virus, cytomegalovirus (CMV), human herpesvirus (HHV) 6A and 6B (HHV-6A and HHV-6B), HHV-7, and Kaposi's sarcoma-associated herpesvirus (KSHV) or HHV-8 (Alba, *et al.*, 2011; Cunningham C, *et al.*, 2010; Davison, 2010; Meyding-Lamade & Strank, 2012; Norberg, 2010), all of which can migrate the immune system and induce the activation of innate and adaptive immune responses by triggering higher secretion and expression of pro-inflammatory cytokines (Scheglovitova, *et al.*, 2002).

KSHV, or HHV-8, is the causative agent of Kaposi's sarcoma (KS), a tumor of lymphatic endothelial origin characterized by proliferating spindle cells containing elements of endothelial and inflammatory cells (Curtiss, *et al.*, 2016; Gramolelli & Ojala, 2017; Kahn, *et al.*, 2002; Naldi, *et al.*, 2018; Weninger, *et al.*, 1999).

Although rare, particularly after the advent of highly active anti-retroviral therapy, KS can disseminate to the CNS in immunosuppressed patients (Bahat, *et al.*, 2002; Gorin, *et al.*, 1985; Jellinger, *et al.*, 2000; Levy, *et al.*, 1984; Mossakowski & Zelman, 1997; Myers, *et al.*, 1974; Pantanowitz & Dezube, 2008; Post, *et al.*, 1986). CNS lesions, when present, typically occur in individuals with concurrent visceral involvement (Gorin, *et al.*, 1985). Lesions are highly vascularized, often display central necrosis, and can be associated with contemporaneous infection with other opportunistic organisms (Bahat, *et al.*, 2002; Barton, *et al.*, 1983; Myers, *et al.*, 1974; Rwomushana, *et al.*, 1975; Vilaseca, *et al.*, 1982; Welch, *et al.*, 1984). KS-associated tumors can involve the cerebrum, cerebellum and dura matter (Ariza & Kim, 1988; Barton, *et al.*, 1983; Buttner, *et al.*, 1997; Myers, *et al.*, 1974; Rwomushana, *et al.*, 1975; Vilaseca, *et al.*, 1982; Welch, *et al.*, 1984), resulting in subdural hematoma, paresis, tonic clonic seizures, among neurological deficits (Ariza & Kim, 1988; Bahat, *et al.*, 2002; Gorin, *et al.*, 1985).

KSHV has long been shown to increase the secretion of angiogenic factors and inflammatory factors and to induce the activation of the PI3K/Akt signaling pathway (Dimaio & Lagunoff, 2012; Kang T, *et al.*, 2008; Purushothaman, *et al.*, 2016). However, the role of ET-1 in the pathogenesis of KSHV infection is still unclear. While some investigators demonstrate no increase in ET-1 during KS (Cacoub, *et al.*, 1995), others have demonstrated

an increase in big ET-1, the ET-1 precursor, during infection with KSHV (Speciale, *et al.*, 2006). Bagnato and colleagues have demonstrated that ET-1 and its receptors are critical to angiogenesis and proliferation of KS tumors (Bagnato, *et al.*, 2001; Bagnato, *et al.*, 2011; Rosano, *et al.*, 2003), with dual ET_A/ET_B receptor blockage abrogating ET-1-induced KS cell invasion and tumor growth and migration both *in vitro* and in an *in vivo* model of local cutaneous invasion (Bagnato, *et al.*, 2001; Rosano, *et al.*, 2003). While these data suggest that ET-1 is involved in the virulence and dissemination of KSHV-induced tumors, the effects of ET-1 on distant disease, including CNS disease, remains to be investigated.

Studies on the involvement of ET-1 in the pathogenesis of other herpes viruses are limited. There is evidence that CMV infection causes an increase in ET_B receptor expression (Yaiw, *et al.*, 2015), suggesting a potential role for ET-1 and its receptors in the pathogenesis of the virus. Scheglovitova and colleagues demonstrated that the effects of HSV-1 on endothelial production of ET-1 is pleiotropic and is dependent on the baseline spontaneous production of ET-1 from those cells and on interferon activation (Scheglovitova, *et al.*, 2013). However, although herpesviruses are associated with CNS pathology, including increased secretion of pro-inflammatory mediators from circulatory immune cells which can traverse the BBB (Conrady, *et al.*, 2010; DeBiasi, *et al.*, 2002; Deigendesch & Stenzel, 2017; Harris & Harris, 2015; Koyuncu, *et al.*, 2013; Marques, *et al.*, 2006; Martino, *et al.*, 2000), there is a paucity of investigations on a role for ET-1 in this process.

Flaviviruses—The *Flaviviridae* family consists of positive, single-stranded enveloped RNA viruses which can occasionally cause severe disease and mortality in humans and animals (Fernandez-Garcia, *et al.*, 2009; Kimura T, *et al.*, 2010). These vector-transmitted viruses include - Yellow Fever, Dengue virus (DENV), Japanese encephalitis virus, Chikungunya virus, West Nile virus and Zika virus (Brehin, *et al.*, 2008; Chen LH & Wilson, 2016; Das, *et al.*, 2010; Fernandez-Garcia, *et al.*, 2009; Huang YJ, *et al.*, 2014; Jhan, *et al.*, 2017; Kimura T, *et al.*, 2010; Lannes, *et al.*, 2017; Lindenbach & Rice, 2003; Lum, *et al.*, 2017). Disease from flaviviruses can range from asymptomatic to symptomatic manifestations, with high fever, chills, headache, back and muscle aches, dizziness, anorexia, nausea, and vomiting (Gould & Solomon, 2008; Murphy BR & Whitehead, 2011), and can sometimes result in fatal illness, such as encephalitis and hemorrhagic fever (Basu, *et al.*, 2016; Imaizumi, *et al.*, 2005). In addition, flavivirus infections can cause inflammation of the CNS (Furr & Marriott, 2012; Roach & Alcendor, 2017; Tsai, *et al.*, 2016).

DENV infection results in important clinical symptoms which include fever, headache and rash (Guabiraba & Ryffel, 2014) (Singhi, *et al.*, 2007; Thomas EA, *et al.*, 2010). However, acute infection may result in severe disease such as in dengue hemorrhagic fever and dengue shock syndrome (Guabiraba & Ryffel, 2014; Halstead, 2002). DENV has been shown to affect several vital organs, including the liver, heart, kidneys, and the brain (Basu & Chaturvedi, 2008). DENV invades the CNS by migrating through CNS through BBB disruption, inducing encephalitis (Li GH, *et al.*, 2017; Li H, *et al.*, 2017; Verma, *et al.*, 2014). These syndromes prominently feature vascular leakage (Tsai, *et al.*, 2016; van de Weg, *et al.*, 2014). Interestingly, van de Weg and colleagues recently demonstrated that endothelial damage in patients infected with DENV was associated with significantly increased plasma levels of ET-1 (van de Weg, *et al.*, 2014). Plasma leakage during DENV infection can lead to

hypovolemic shock, coagulopathy, bleeding, organ impairment and death (Simmons, *et al.*, 2012). Furthermore, DENV infection of endothelial cells may induce injury to the brain microvasculature, resulting in increased secretion of pro-inflammatory cytokines and chemokines in the cerebral microvascular milieu (Basu & Chaturvedi, 2008; Cardier, *et al.*, 2006; Hendarto & Hadinegoro, 1992; Solomon, *et al.*, 2000; van de Weg, *et al.*, 2014).

While it is well established that flaviviruses enter into the CNS, to infect glial cells, and elicit a robust immune response, a relationship between such events and ET-1 has not been established.

Several viral infections of the CNS are associated with an increase in the secretion of ET-1 by activated endothelial cells, inflammatory cells, and glial cells, particularly astrocytes and microglia (Chauhan, *et al.*, 2007; Didier, *et al.*, 2002; Didier, *et al.*, 2003; Ehrenreich, *et al.*, 1993; Ma, *et al.*, 1994; Zhang WW, *et al.*, 1994). As of the time of this review, causative relationships between the pathological increase in ET-1 secretion and vascular dysfunction with resultant loss of BBB integrity or the robust immune response that occur during infection remains to be assessed. However, previous studies of parasitic diseases of the brain suggest that ET-1 likely plays an integral role in the pathogenesis of these infections in the CNS (Dai, *et al.*, 2012; Freeman, *et al.*, 2014; Freeman, *et al.*, 2016; Martins, *et al.*, 2016). Thus, further investigations are warranted to determine the role of ET-1 in the pathogenesis of neurological dysfunction during viral illnesses.

ENDOTHELIN-1 AND CENTRAL NERVOUS SYSTEM VASCULITIS.

Potential roles of the Endothelin-1 pathway in Central Nervous System Vasculitis

ET-1 secreted predominantly by the endothelial cells (Yanagisawa M, *et al.*, 1988) is found in high intramural concentrations in several inflammatory diseases of the vascular wall (Battistini, *et al.*, 1993). Of relevance to the present section, systemic lupus erythematosus (SLE) has been associated with high levels of plasma levels of ET-1 in patients (Dhaun, *et al.*, 2009; Julkunen, *et al.*, 1991). Furthermore, cultured endothelial cells exhibited increased secretion of ET-1 after exposure to sera from patients with SLE (Yoshio, *et al.*, 1995). Nakamura and colleagues previously demonstrated that selective ET_A antagonism prevented the progression of lupus nephritis in a murine model (Nakamura, *et al.*, 1995), and more recently, Li Guo and colleagues showed that SLE patients with autoantibodies to ET_A were more likely to develop pulmonary hypertension (Guo L, *et al.*, 2015). Although there has not been any clear associations between ET-1 and neuropsychiatric SLE, high concentrations of vascular ET-1 have been observed in vasculitis-prone MRL/lpr mice (Sugimoto, *et al.*, 2017), an established model of SLE (Perry D, *et al.*, 2011), which has been well characterized as a model of spontaneous neuropsychiatric lupus (Gao, *et al.*, 2009; Gulinello & Putterman, 2011; Gulinello, *et al.*, 2012; Stock, *et al.*, 2015; Wen, *et al.*, 2013), with clear leukocyte infiltration to the choroid plexuses and breach of the blood-brain barrier (Mike, *et al.*, 2018).

In Experimental Autoimmune Encephalomyelitis (EAE), an animal model of multiple sclerosis, mice that overexpress endothelial and astrocytic ET-1 present more severe inflammation and demyelination (Guo Y, *et al.*, 2014). These outcomes are possibly the

result of ET-1- induced alteration of the integrity of myelin sheets in the spinal cord via a Notch-1-dependent mechanism as well as suppression of oligodendrocyte progenitor cell-dependent repair of demyelinated neurons by the peptide (Hammond, *et al.*, 2015). Correspondingly, investigators have demonstrated that repression of one of the mouse chymases, mouse Mast Cell Protease 4 (mMCP-4), mitigates disease-related increases in brain ET-1 levels during EAE (Desbiens, *et al.*, 2016).

Thus, repressing the brain production of ET-1 with a chymase inhibitor may facilitate myelin repair in neurogenerative diseases such as Multiple Sclerosis (MS). Interestingly, more than 30 years ago, inflammatory vasculitis had been reported especially in lesioned sections of the spinal cord of MS patients more than 30 years ago (Adams CW, *et al.*, 1985). The role of chymase-dependent production of ET-1 in the development of vasculitis in MS patients, however, remains poorly understood. Nonetheless, in light of the importance of mast cell-derived chymase in ET-1 generation (see Introduction), we suggest that targeting chymase rather than the ECE to treat CSNV may be preferable. Indeed, homozygous repression of mMCP-4 does not prompt the impairment of embryonic development in genetically engineered mice (Tchougounova, *et al.*, 2003). Furthermore, pharmacological interference with an ECE inhibitor enhances amyloid plaque formation (Eckman, *et al.*, 2001; Pacheco-Quinto, *et al.*, 2013; Wang S, *et al.*, 2010).

ET-1 and ET receptors in Giant Cell Arteritis

Tissular levels of ET-1 and of its ET_B receptors are significantly increased in arteries derived from inflammation prone-patients with giant cells arteritis (GCA). In a recent study, Regent and colleagues (2017) reported that the dual ET_A/ET_B antagonist macitentan combined with glucocorticoids, reduced vascular smooth muscle cell (VSMC) proliferation in vessels of patients with GCA (Regent, *et al.*, 2017). Planas-Rigol and colleagues demonstrated that ET-1 immunoreactivity was predominant in leucocytes infiltrating the medial-intima interphases of vessels derived from GCA patients and that both ET_A and ET_B receptors in VSMC proliferation in such vessels through activation of Focal Adhesion Kinase (Planas-Rigol, *et al.*, 2017).

Mast cells and Central Nervous System Vasculitis

The role of mast cells in the etiology of CNS vasculitis (CNSV) remains controversial. While some groups have suggested protective roles of those cells in large vessel vasculitis via histamine-dependent repression of pro-inflammatory IL- (Springer, *et al.*, 2017), others have suggested that hyperactivated mastocytes contribute to inflammatory-dependent deterioration of blood vessels (Kiely, *et al.*, 1997; Lipitsa, *et al.*, 2015). Kiely and colleagues reported a role for mast cells in the genesis of mercuric chloride-induced vasculitis in Brown Norway rats (Kiely, *et al.*, 1997). Furthermore, Lipitsa et al. demonstrated that mastocyte-derived chymase is directly involved in intramural deposition of immunoreactants in the vascular wall (Lipitsa, *et al.*, 2015). Pro-inflammatory mast cells are predominantly located on the abluminal side of blood vessels and can readily cross the BBB to gain direct contact with astrocytes, glial cells and other cellular moieties involved in the maintenance of the brain integrity, especially in diseases states (Silverman, *et al.*, 2000).

Furthermore, cross-talk between mast-cells and Kallikrein-Kinin has been implicated in inflammatory propagation and enhanced cardiac parasitism and fibrosis in *T. cruzi*-infected mice (Nascimento, *et al.*, 2017) yet it remains to be investigated if a similar cross talk comes into play within the BBB in CNSV.

The current state of knowledge on potential roles of ET-1 in inflammation-prone vasculitis of the CNS has been summarized. The mechanistic basis of this type of vascular dysfunction remains to be investigated, although its occurrence increases in several bacterial and viral-induced infections of the CNS. Targeting chymase rather than the overall mastocytic activity might represent a more effective approach to treating CNSV due to the neuroprotective roles mast cells reported in large vessel vasculitis.

ROLE OF ET-1 IN ALZHEIMER'S DISEASE

Alzheimer's Disease (AD) is one of the most common and devastating neurodegenerative diseases (Xie, *et al.*, 2014), and is characterized by a substantial loss of neurons in the brain, which may lead to progressive memory decline and a deficits in cognitive functions (Ubhi & Masliah, 2013). These neuronal degenerative alterations in AD are induced by a number of factors which include beta-amyloid deposition, microtubule destabilization, deficiencies in neuronal communication and secretion of pro-inflammatory cytokines and chemokines (Wang DB, *et al.*, 2010). The development of neurodegenerative pathologies, such as Alzheimer's disease, may be linked to environmental and genetic factors (Barber, 2012; El Gaamouch, *et al.*, 2016; Grant, *et al.*, 2002; Tanzi & Bertram, 2001; Tol, *et al.*, 1999).

While the etiology of neurodegenerative diseases such as AD is multifactorial, the primary factors that initiate AD pathogenesis are soluble and aggregated neurotoxic beta-amyloid protein (A β) and hyperphosphorylated tau which induce inflammatory activation of glial cells (Guerriero, *et al.*, 2016; Schwartz & Deczkowska, 2016). Amyloid plaques, consisting of extracellular A β deposits from amyloid precursor protein (APP), and neurofibrillary tangles, composed of aggregates of misfolded and tau proteins, within neurons are typical characteristics of AD pathology (Lacosta, *et al.*, 2017; Murphy MP & LeVine, 2010). Levels of A β in the brain are regulated by the relative rates of A β production and clearance over time (Jeong, 2017; Sun, *et al.*, 2015), which under normal homeostatic conditions, are both rapid (Bateman, *et al.*, 2006; Mawuenyega, *et al.*, 2010). There are two A β peptides that result from the amyloidogenic processing of APP, namely the soluble A β ₁₋₄₀ and the less soluble and more toxic A β ₁₋₄₂ (Kirkitadze & Kowalska, 2005; Serrano-Pozo, *et al.*, 2011). Excessive increase in A β ₁₋₄₂ or an increase in the A β ₁₋₄₂: A β ₁₋₄₀ ratio are thought to be pivotal to the etiology of the pathological cascade in AD patients (Palmer & Love, 2011).

Vascular dysfunction also plays an important role in the development of AD (Dickstein, *et al.*, 2010). Recent data from brain imaging studies in humans and in experimental AD animal models suggest that cerebrovascular dysfunction may precede cognitive decline and onset of neurodegenerative changes in AD (Klohs, *et al.*, 2014; Montagne, *et al.*, 2017). ET-1 has been studied extensively as a mediator of vasomodulation, and the dysregulation of the endothelin system is instrumental to the progression of AD (Palmer, *et al.*, 2013). Many studies have demonstrated that the concentration of ET-1 is increased in both the cerebral

cortex (Minami, *et al.*, 1995; Palmer, *et al.*, 2012) and in cerebral blood vessels in AD (Luo & Grammas, 2010; Palmer, *et al.*, 2013). This is in association with significant increases in A β which indirectly stimulates production of ET-1 (Pacheco-Quinto & Eckman, 2013; Pacheco-Quinto, *et al.*, 2013; Palmer, *et al.*, 2013). The exposure of human neuroblastoma cells and brain microvascular endothelial cells to A β induced increases in the expression of ECE-2 and ECE-1, resulting in increased production and secretion of ET-1 (Palmer, *et al.*, 2009; Palmer, *et al.*, 2012; Palmer, *et al.*, 2013). In addition, ET-1 production is increased in the cerebral vasculature of mice infused with A β (Paris, *et al.*, 2003). ET-1 expression is also modulated by astrocytes in AD and a number of other brain pathologies (D'Haeseleer, *et al.*, 2013; Hammond, *et al.*, 2014; Palmer, *et al.*, 2012; Petrov, *et al.*, 2002; Schinelli, 2006; Stiles, *et al.*, 1997). Both astrocyte and glial cells can contribute to the development of secondary brain damage by activating ET receptors in both an autocrine and paracrine manner (Barker, *et al.*, 2014; Esiri, 2007; Hostenbach, *et al.*, 2016).

Most individuals with AD exhibit cognitive impairment and a reduction in CBF before the onset of dementia. (Palmer, *et al.*, 2013). The correlation between cerebral vasoconstriction and microvascular endothelial cell dysfunction further leads to further ET-1 secretion and the release of free radicals which are toxic to neurons (Stankowska, *et al.*, 2017). Hypoxia itself can upregulate components of the endothelin system (Ao, *et al.*, 2002; Kang BY, *et al.*, 2011; Li, *et al.*, 1994; Yamashita, *et al.*, 2001). In AD, chronic cerebral hypoperfusion and glucose hypometabolism can result in cognitive decline with time (Daulatzai, 2017). Brain hypoperfusion is assessed by documenting a reduced ratio of myelin-associated glycoprotein compared to proteolipid protein-1 (Barker, *et al.*, 2013; Barker, *et al.*, 2014; Thomas T, *et al.*, 2015) and the decrease in this ratio strongly correlates with the increased expression in ET-1 during AD (Barker, *et al.*, 2014; Love & Miners, 2016; Thomas T, *et al.*, 2015). Significant reduction in CBF has been associated with the presence of white matter lesions in AD resulting in more rapid progression to cognitive impairment compared to AD patients without white matter lesions (Hanaoka, *et al.*, 2016; Kimura N, *et al.*, 2012).

While there is a clear vascular component to the development of AD, it should be noted that neurological and neurodegenerative diseases may be influenced by other factors such as aging, infection (bacteria, virus, parasite) and inflammatory activation (Amor, *et al.*, 2010; De Chiara, *et al.*, 2012). In fact, there are several reports of chronic neuroinflammation due to injury or infection in association with the onset and progression of AD and other neurodegenerative diseases including Parkinson's disease and Multiple Sclerosis (Chen WW, *et al.*, 2016), manifested by activation of microglia, astrocytes, mast cells, T-cells, and inflammatory mediators released from these cells (Shabab, *et al.*, 2017). AD is characterized by glial cell activation, transmigration of macrophages into the brain parenchyma, and accumulation of several essential proteins (Sokolova, *et al.*, 2009; Walter, *et al.*, 2007). It is widely thought that the accumulation of the A β is central in the pathogenesis of the disease, as it causes dysfunction and loss of synapses that lead to cognitive deficits (Murphy MP & LeVine, 2010; Sadigh-Eteghad, *et al.*, 2015). Interestingly, ET-1 has been shown to contribute to the inflammatory process induced by A β . In a study by Bryial and colleagues, animals were treated with amyloid beta, resulting in increased the expression of the components of ET signaling, oxidative stress, and in cognitive impairment. Treatment with a selective ET_A receptor antagonist mitigated these changes (Briyal, *et al.*, 2011)

In summary, recent evidence suggests that ET-1 likely contributes to loss of endothelial functional integrity and cerebrovascular inflammation, by both direct and indirect actions on the cerebral vasculature, leading to neurodegeneration. This provides a potential role for ET-1 in the pathogenesis of AD and a target of therapy.

CONCLUSION

The mechanisms associated with the roles of the endothelin pathways in neuroinflammatory diseases are highly complex. A common pattern nonetheless is recognizable as in all the above described diseases, pathogen-triggered inflammatory response plays a pivotal role in the increase of tissue and/or blood levels of ET-1. This important cross-talk occurs within and outside of the CNS and involves the activation of either or both ET_A and ET_B receptors whose expression, in some of the diseases discussed above, can be independently or conjointly modulated. In most parasitic diseases described, ET-1 appears to be closely associated with a loss of endothelial integrity as well as changes in BBB permeability. Although interfering with the ET-1 pathway has been successful in reducing morbidity in experimental models of neuro-inflammatory infections, it remains to be validated whether the potent vasoactive peptide is a marker or a mediator in most neurological diseases studied in patients.

Acknowledgments

The authors thank Mario Desbiens for artistic support. This work was supported by a Joseph C. Edwards Cardiology Chair (PD-J), Studentship from the Fonds de la Recherche Québec en Santé (LD), Yale University Faculty Excellence and Diversity Initiative award (MSD), the Canadian Institutes of Health Research (MOP-57883) (PD-J), and the United States National Institutes of Health: Grants AI076248 (HBT), NS069577 (MSD).

This review is dedicated to the memory of Dr. Herbert B. Tanowitz, MD (September 6, 1941 - July 17, 2018), Professor of Pathology and Medicine at the Albert Einstein College of Medicine. Dr. Tanowitz was an esteemed colleague, a friend and mentor who pioneered the studies of endothelin in parasitic diseases.

LIST OF ABBREVIATIONS

AD	Alzheimer's Disease
APP	Amyloid precursor protein
Aβ	Beta-amyloid protein
BBB	Blood-brain barrier
CNS	Central nervous system
CBF	Cerebral blood flow
CM	Cerebral malaria
CXCL	Chemokine (C-X-C motif) ligand
CCL	Chemokine (C-C motif) ligand
CNSV	CNS vasculitis

CMV	Cytomegalovirus
DENV	Dengue virus
ET	Endothelin
ET-1	Endothelin-1
ECE	Endothelin converting enzyme
ET_B	Endothelin subtype B
ET_A	Endothelin subtype A
EAE	Experimental Autoimmune Encephalomyelitis
GCA	Giant cells arteritis
HSV-1	Herpes simplex virus 1
HSV-2	Herpes simplex virus 2
HHV	Human herpesvirus
HIV	Human immunodeficiency virus
HAND	HIV-associated neurocognitive disorders
ICAM-1	Intercellular cell adhesion molecule 1
KS	Kaposi's sarcoma
KSHV	Kaposi's sarcoma-associated herpesvirus
MS	Multiple Sclerosis
NO	Nitric oxide
SLE	Systemic lupus erythematosus
VCAM-1	Vascular cell adhesion protein 1
VSMC	Vascular smooth muscle cell

REFERENCES

- Adams CW, Poston RN, Buk SJ, Sidhu YS, & Vipond H (1985). Inflammatory vasculitis in multiple sclerosis. *J Neurol Sci*, 69, 269–283. [PubMed: 4031947]
- Adams S, Brown H, & Turner G (2002). Breaking down the blood-brain barrier: signaling a path to cerebral malaria? *Trends Parasitol*, 18, 360–366. [PubMed: 12377286]
- Alba MA, Espigol-Frigole G, Prieto-Gonzalez S, Tavera-Bahillo I, Garcia-Martinez A, Butjosa M, Hernandez-Rodriguez J, & Cid MC (2011). Central nervous system vasculitis: still more questions than answers. *Curr Neuroparmacol*, 9, 437–448. [PubMed: 22379458]
- Alencar A, & Elejalde P (1960). O sistema nervoso central na infestação experimental do camundongo albino pelo *Schizotrypanum cruzi*. *J Brasil Neurol*, 12, 49–57.

- Alencar A (1964). [Clinical and Biological Aspects of Neurological and Muscular Manifestations of South American Trypanosomiasis (Chagas' Disease)]. *Rev Neuropsiquiatr*, 27, 57–69. [PubMed: 14301263]
- Amor S, Puentes F, Baker D, & van der Valk P (2010). Inflammation in neurodegenerative diseases. *Immunology*, 129, 154–169. [PubMed: 20561356]
- Ances BM, & Ellis RJ (2007). Dementia and neurocognitive disorders due to HIV-1 infection. *Semin Neurol*, 27, 86–92. [PubMed: 17226745]
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, & Wojna VE (2007). Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*, 69, 1789–1799. [PubMed: 17914061]
- Antinori A, Trotta MP, Lorenzini P, Torti C, Gianotti N, Maggiolo F, Ceccherini-Silberstein F, Nasto P, Castagna A, De Luca A, Mussini C, Andreoni M, Perno CF, & Group GS (2007). Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. *Antivir Ther*, 12, 1175–1183. [PubMed: 18240858]
- Ao Q, Hao C, Xiong M, & Wang D (2002). Expression of hypoxia-inducible factor-1 alpha and endothelin-1 gene in hypoxic pulmonary hypertension. *Zhonghua Bing Li Xue Za Zhi*, 31, 140–142. [PubMed: 12419162]
- Arai H, Hori S, Aramori I, Ohkubo H, & Nakanishi S (1990). Cloning and expression of a cDNA encoding an endothelin receptor. *Nature*, 348, 730–732. [PubMed: 2175396]
- Ariza A, & Kim JH (1988). Kaposi's sarcoma of the dura mater. *Hum Pathol*, 19, 1461–1463. [PubMed: 3192208]
- Ashton AW, Mukherjee S, Nagajyothi FN, Huang H, Braunstein VL, Desruisseaux MS, Factor SM, Lopez L, Berman JW, Wittner M, Scherer PE, Capra V, Coffman TM, Serhan CN, Gotlinger K, Wu KK, Weiss LM, & Tanowitz HB (2007). Thromboxane A2 is a key regulator of pathogenesis during *Trypanosoma cruzi* infection. *J Exp Med*, 204, 929–940. [PubMed: 17420269]
- Avalos CR, Abreu CM, Queen SE, Li M, Price S, Shirk EN, Engle EL, Forsyth E, Bullock BT, Mac Gabhann F, Wietgreffe SW, Haase AT, Zink MC, Mankowski JL, Clements JE, & Gama L (2017). Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir. *MBio*, 8.
- Bagnato A, Rosano L, Di Castro V, Albini A, Salani D, Varmi M, Nicotra MR, & Natali PG (2001). Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. *Am J Pathol*, 158, 841–847. [PubMed: 11238033]
- Bagnato A, Loizidou M, Pflug BR, Curwen J, & Growcott J (2011). Role of the endothelin axis and its antagonists in the treatment of cancer. *Br J Pharmacol*, 163, 220–233. [PubMed: 21232046]
- Bahat E, Akman S, Karpuzoglu G, Aktan S, Ucar T, Arslan AG, Nenonen N, Guven AG, & Karpuzoglu T (2002). Visceral Kaposi's sarcoma with intracranial metastasis: a rare complication of renal transplantation. *Pediatr Transplant*, 6, 505–508. [PubMed: 12453204]
- Barber RC (2012). The genetics of Alzheimer's disease. *Scientifica (Cairo)*, 2012, 246210. [PubMed: 24278680]
- Barker R, Wellington D, Esiri MM, & Love S (2013). Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins. *J Cereb Blood Flow Metab*, 33, 1050–1057. [PubMed: 23532085]
- Barker R, Ashby EL, Wellington D, Barrow VM, Palmer JC, Kehoe PG, Esiri MM, & Love S (2014). Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. *Brain*, 137, 1524–1532. [PubMed: 24618270]
- Barnes K, & Turner AJ (1997). The endothelin system and endothelin-converting enzyme in the brain: molecular and cellular studies. *Neurochem Res*, 22, 1033–1040. [PubMed: 9239759]
- Barnes K, & Turner AJ (1999). Endothelin converting enzyme is located on alpha-actin filaments in smooth muscle cells. *Cardiovasc Res*, 42, 814–822. [PubMed: 10533622]
- Barton NW, Safai B, Nielsen SL, & Posner JB (1983). Neurological complications of Kaposi's sarcoma. An analysis of 5 cases and a review of the literature. *J Neurooncol*, 1, 333–346. [PubMed: 6381658]

- Basu A, & Chaturvedi UC (2008). Vascular endothelium: the battlefield of dengue viruses. *FEMS Immunol Med Microbiol*, 53, 287–299. [PubMed: 18522648]
- Basu A, Yadav P, Prasad S, Badole S, Patil D, Kohlapure RM, & Mourya DT (2016). An Early Passage Human Isolate of Kyasanur Forest Disease Virus Shows Acute Neuropathology in Experimentally Infected CD-1 Mice. *Vector Borne Zoonotic Dis*, 16, 496–498. [PubMed: 27171207]
- Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, & Holtzman DM (2006). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. *Nat Med*, 12, 856–861. [PubMed: 16799555]
- Battistini B, D'Orleans-Juste P, & Sirois P (1993). Endothelins: circulating plasma levels and presence in other biologic fluids. *Lab Invest*, 68, 600–628. [PubMed: 8515652]
- Bellapart J, Jones L, Bandeshe H, & Boots R (2014). Plasma endothelin-1 as screening marker for cerebral vasospasm after subarachnoid hemorrhage. *Neurocrit Care*, 20, 77–83. [PubMed: 23921571]
- Ben Younes-Chennoufi A, Hontebeyrie-Joskowicz M, Tricottet V, Eisen H, Reynes M, & Said G (1988). Persistence of *Trypanosoma cruzi* antigens in the inflammatory lesions of chronically infected mice. *Trans R Soc Trop Med Hyg*, 82, 77–83. [PubMed: 3140446]
- Bennett BA, Rusyniak DE, & Hollingsworth CK (1995). HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. *Brain Res*, 705, 168–176. [PubMed: 8821747]
- Bern C, & Montgomery SP (2009). An estimate of the burden of Chagas disease in the United States. *Clin Infect Dis*, 49, e52–e54. [PubMed: 19640226]
- Bern C, Martin DL, & Gilman RH (2011). Acute and congenital Chagas disease. *Adv Parasitol*, 75, 19–47. [PubMed: 21820550]
- Birbeck GL, Molyneux ME, Kaplan PW, Seydel KB, Chimalizeni YF, Kawaza K, & Taylor TE (2010). Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. *Lancet Neurol*, 9, 1173–1181. [PubMed: 21056005]
- Bittencourt AL (1976). Congenital Chagas disease. *Am J Dis Child*, 130, 97–103. [PubMed: 813519]
- Blais V, Fugere M, Denault JB, Klarskov K, Day R, & Leduc R (2002). Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. *FEBS Lett*, 524, 43–48. [PubMed: 12135739]
- Bouallegue A, Daou GB, & Srivastava AK (2007). Endothelin-1-induced signaling pathways in vascular smooth muscle cells. *Curr Vasc Pharmacol*, 5, 45–52. [PubMed: 17266612]
- Boven LA, Middel J, Breij EC, Schotte D, Verhoef J, Soderland C, & Nottet HS (2000). Interactions between HIV-infected monocyte-derived macrophages and human brain microvascular endothelial cells result in increased expression of CC chemokines. *J Neurovirol*, 6, 382–389. [PubMed: 11031691]
- Brandao HJ, & Zulian R (1966). Nerve cell depopulation in chronic Chagas' disease. A quantitative study in the cerebellum. *Rev Inst Med Trop Sao Paulo*, 8, 281–286. [PubMed: 4969535]
- Brehin AC, Mouries J, Frenkiel MP, Dadaglio G, Despres P, Lafon M, & Couderc T (2008). Dynamics of immune cell recruitment during West Nile encephalitis and identification of a new CD19+B220-BST-2+ leukocyte population. *J Immunol*, 180, 6760–6767. [PubMed: 18453596]
- Britto-Costa R (1971). [Hypothalamic changes in the chronic phase of experimental chagas' disease]. *Rev Inst Med Trop Sao Paulo*, 13, 336–345. [PubMed: 5005698]
- Briyal S, Philip T, & Gulati A (2011). Endothelin-A Receptor Antagonists Prevent Amyloid- β -Induced Increase in ETA Receptor Expression, Oxidative Stress, and Cognitive Impairment. *Journal of Alzheimer's Disease*, 23, 491–503.
- Buckner FS, Wilson AJ, & Van Voorhis WC (1999). Detection of live *Trypanosoma cruzi* in tissues of infected mice by using histochemical stain for beta-galactosidase. *Infect Immun*, 67, 403–409. [PubMed: 9864242]
- Buttner A, Marquart KH, Mehraein P, & Weis S (1997). Kaposi's sarcoma in the cerebellum of a patient with AIDS. *Clin Neuropathol*, 16, 185–189. [PubMed: 9266142]
- Cabrales P, Zanini GM, Meays D, Frangos JA, & Carvalho LJ (2010). Murine cerebral malaria is associated with a vasospasm-like microcirculatory dysfunction, and survival upon rescue treatment

is markedly increased by nimodipine. *American Journal of Pathology*, 176, 1306–1315. [PubMed: 20110412]

- Cacoub P, Coutellier A, Maistre G, de Gennes C, Frances C, Piette JC, & Godeau P (1995). Plasma endothelin and Kaposi's sarcoma. *J Am Acad Dermatol*, 32, 1048–1049. [PubMed: 7751451]
- Caradonna K, & Pereiraperrin M (2009). Preferential brain homing following intranasal administration of *Trypanosoma cruzi*. *Infect Immun*, 77, 1349–1356. [PubMed: 19168740]
- Cardier JE, Rivas B, Romano E, Rothman AL, Perez-Perez C, Ochoa M, Caceres AM, Cardier M, Guevara N, & Giovannetti R (2006). Evidence of vascular damage in dengue disease: demonstration of high levels of soluble cell adhesion molecules and circulating endothelial cells. *Endothelium*, 13, 335–340. [PubMed: 17090406]
- Carod-Artal FJ, & Gascon J (2010). Chagas disease and stroke. *Lancet Neurol*, 9, 533–542. [PubMed: 20398860]
- Carod-Artal FJ, Vargas AP, & Falcao T (2011). Stroke in asymptomatic *Trypanosoma cruzi*-infected patients. *Cerebrovascular Diseases*, 31, 24–28. [PubMed: 20980750]
- Carod-Artal FJ (2013). American trypanosomiasis. *Handb Clin Neurol*, 114, 103–123. [PubMed: 23829903]
- Carroll A, & Brew B (2017). HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. *F1000Res*, 6, 312. [PubMed: 28413625]
- Carter JA, Lees JA, Gona JK, Murira G, Rimba K, Neville BG, & Newton CR (2006). Severe falciparum malaria and acquired childhood language disorder. *Dev Med Child Neurol*, 48, 51–57. [PubMed: 16359594]
- Chagas C (1911). Nova entidade morbida do homem: Rezumo geral de estudos etiológicos e clínicos. *Memorias do Instituto Oswaldo Cruz*, 3, 219–275.
- Chagas C (1913). Les formes nerveuses d'une nouvelle Trypanosomiase. *Nouv Iconogr Salpetr*, 26, 1–8.
- Chauhan A, Hahn S, Gartner S, Pardo CA, Netesan SK, McArthur J, & Nath A (2007). Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins. *Faseb J*, 21, 777–789. [PubMed: 17197385]
- Chavez-Bueno S, & McCracken GH, Jr. (2005). Bacterial meningitis in children. *Pediatric Clinics of North America*, 52, 795–810, vii. [PubMed: 15925663]
- Chen LH, & Wilson ME (2016). Update on non-vector transmission of dengue: relevant studies with Zika and other flaviviruses. *Trop Dis Travel Med Vaccines*, 2, 15. [PubMed: 28883959]
- Chen P, Shibata M, Zidovetzki R, Fisher M, Zlokovic BV, & Hofman F (2001). Endothelin-1 and monocyte chemoattractant protein-1 modulation in ischemia and human brain-derived endothelial cell cultures. *Journal of Neuroimmunology*, 116, 62–73. [PubMed: 11311331]
- Chen WW, Zhang X, & Huang WJ (2016). Role of neuroinflammation in neurodegenerative diseases (Review). *Mol Med Rep*, 13, 3391–3396. [PubMed: 26935478]
- Chew BH, Weaver DF, & Gross PM (1995). Dose-related potent brain stimulation by the neuropeptide endothelin-1 after intraventricular administration in conscious rats. *Pharmacol Biochem Behav*, 51, 37–47. [PubMed: 7617731]
- Chuenkova MV, & Pereiraperrin M (2011). Neurodegeneration and neuroregeneration in Chagas disease. *Adv Parasitol*, 76, 195–233. [PubMed: 21884893]
- Conrady CD, Drevets DA, & Carr DJ (2010). Herpes simplex type I (HSV- infection of the nervous system: is an immune response a good thing? *J Neuroimmunol*, 220, 1–9. [PubMed: 19819030]
- Cotter R, Williams C, Ryan L, Erichsen D, Lopez A, Peng H, & Zheng J (2002). Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia. *J Neurovirol*, 8, 585–598. [PubMed: 12476352]
- Cunningham C, Gatherer D, Hilfrich B, Baluchova K, Dargan DJ, Thomson M, Griffiths PD, Wilkinson GW, Schulz TF, & Davison AJ (2010). Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. *J Gen Virol*, 91, 605–615. [PubMed: 19906940]
- Cunningham ME, Huribal M, Bala RJ, & McMillen MA (1997). Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. *Crit Care Med*, 25, 958–964. [PubMed: 9201047]

- Curtiss P, Strazzulla LC, & Friedman-Kien AE (2016). An Update on Kaposi's Sarcoma: Epidemiology, Pathogenesis and Treatment. *Dermatol Ther (Heidelb)*, 6, 465–470. [PubMed: 27804093]
- D'Amico M, Berrino L, Maione S, Filippelli A, de Novellis V, & Rossi F (1996). Endothelin-1 in periaqueductal gray area of mice induces analgesia via glutamatergic receptors. *Pain*, 65, 205–209. [PubMed: 8826508]
- D'Haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM, Verborgh C, Demey J, & De Keyser J (2013). Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. *Proc Natl Acad Sci U S A*, 110, 5654–5658. [PubMed: 23509249]
- D'Orleans-Juste P, Plante M, Honore JC, Carrier E, & Labonte J (2003). Synthesis and degradation of endothelin-1. *Can J Physiol Pharmacol*, 81, 503–510. [PubMed: 12839262]
- Dai M, Reznik SE, Spray DC, Weiss LM, Tanowitz HB, Gulinello M, Desruisseaux MS (2010). Persistent cognitive and motor deficits after successful antimalarial treatment in murine cerebral malaria. *Microbes Infect*, 12, 1198–1207. [PubMed: 20800692]
- Dai M, Freeman B, Bruno FP, Shikani HJ, Tanowitz HB, Weiss LM, Reznik SE, Stephani RA, & Desruisseaux MS (2012). The novel ETA receptor antagonist HJP-272 prevents cerebral microvascular hemorrhage in cerebral malaria and synergistically improves survival in combination with an artemisinin derivative. *Life Sci*, 91, 687–692. [PubMed: 22820174]
- Dallasta LM, Pisarov LA, Esplen JE, Werley JV, Moses AV, Nelson JA, & Achim CL (1999). Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. *Am J Pathol*, 155, 1915–1927. [PubMed: 10595922]
- Das Sarma J (2014). Microglia-mediated neuroinflammation is an amplifier of virus-induced neuropathology. *J Neurovirol*, 20, 122–136. [PubMed: 23979705]
- Das T, Jaffar-Bandjee MC, Hoarau JJ, Krejbich Trotot P, Denizot M, Lee-Pat-Yuen G, Sahoo R, Guiraud P, Ramful D, Robin S, Alessandri JL, Gauzere BA, & Gasque P (2010). Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. *Prog Neurobiol*, 91, 121–129. [PubMed: 20026374]
- Daulatzai MA (2017). Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. *J Neurosci Res*, 95, 943–972. [PubMed: 27350397]
- Davi G, Giammarresi C, Vigneri S, Ganci A, Ferri C, Di Francesco L, Vitale G, & Mansueto S (1995). Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. *Thromb Haemost*, 74, 631–634. [PubMed: 8584998]
- Davison AJ (2010). Herpesvirus systematics. *Vet Microbiol*, 143, 52–69. [PubMed: 20346601]
- De Chiara G, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, Garaci E, Grassi C, & Palamara AT (2012). Infectious agents and neurodegeneration. *Mol Neurobiol*, 46, 614–638. [PubMed: 22899188]
- De Queiroz A (1973). Tumor-like lesion of the brain caused by Trypanosoma cruzi. *American Journal of Tropical Medicine and Hygiene*, 22, 473–476. [PubMed: 4197952]
- DeBiasi RL, Kleinschmidt-DeMasters BK, Richardson-Burns S, & Tyler KL (2002). Central nervous system apoptosis in human herpes simplex virus and cytomegalovirus encephalitis. *J Infect Dis*, 186, 1547–1557. [PubMed: 12447729]
- Deigendesch N, & Stenzel W (2017). Acute and chronic viral infections. *Handb Clin Neurol*, 145, 227–243. [PubMed: 28987172]
- Desbiens L, Lapointe C, Gharagozloo M, Mahmoud S, Pejler G, Gris D, & D'Orleans-Juste P (2016). Significant Contribution of Mouse Mast Cell Protease 4 in Early Phases of Experimental Autoimmune Encephalomyelitis. *Mediators Inflamm*, 2016, 9797021. [PubMed: 27610007]
- Desruisseaux MS, Gulinello M, Smith DN, Lee SC, Tsuji M, Weiss LM, Spray DC, & Tanowitz HB (2008). Cognitive dysfunction in mice infected with Plasmodium berghei strain ANKA. *Journal of Infectious Diseases*, 197, 1621–1627. [PubMed: 18419550]
- Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, Webb DJ, & Goddard J (2009). Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. *Am J Physiol Renal Physiol*, 296, F1477–1483. [PubMed: 19279127]

- Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, & Franco-Paredes C (2009). Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. *Lancet Infect Dis*, 9, 324–330. [PubMed: 19393962]
- Dickstein DL, Walsh J, Brautigam H, Stockton SD, Jr., Gandy S, & Hof PR (2010). Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. *Mt Sinai J Med*, 77, 82–102. [PubMed: 20101718]
- Didier N, Banks WA, Creminon C, Dereuddre-Bosquet N, & Mabondzo A (2002). HIV-1-induced production of endothelin-1 in an in vitro model of the human blood-brain barrier. *Neuroreport*, 13, 1179–1183. [PubMed: 12151765]
- Didier N, Romero IA, Creminon C, Wijkhuisen A, Grassi J, & Mabondzo A, (2003). Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. *J Neurochem*, 86, 246–254. [PubMed: 12807444]
- Dietmann A, Lackner P, Helbok R, Spora K, Issifou S, Lell B, Reindl M, Kremsner PG, & Schmutzhard E (2008). Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with *Plasmodium falciparum* malaria. *Malar J*, 7, 253. [PubMed: 19077312]
- Dimaio TA, & Lagunoff M (2012). KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes. *Front Microbiol*, 3, 102. [PubMed: 22479258]
- Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, Kamiza S, Molyneux M, & Taylor TE (2011). The neuropathology of fatal cerebral malaria in malawian children. *American Journal of Pathology*, 178, 2146–2158. [PubMed: 21514429]
- Dreyer EB, Kaiser PK, Offermann JT, & Lipton SA (1990). HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. *Science*, 248, 364–367. [PubMed: 2326646]
- Eckman EA, Reed DK, & Eckman CB (2001). Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. *J Biol Chem*, 276, 24540–24548. [PubMed: 11337485]
- Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, & Fauci AS (1990). Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. *Journal of Experimental Medicine*, 172, 1741–1748. [PubMed: 1701822]
- Ehrenreich H, Burd PR, Rottem M, Hultner L, Hylton JB, Garfield M, Coligan JE, Metcalfe DD, & Fauci AS (1992). Endothelins belong to the assortment of mast cell-derived and mast cell-bound cytokines. *New Biol*, 4, 147–156. [PubMed: 1313283]
- Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, Burd PR, Coligan JE, & Clouse KA (1993). Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. *J Immunol*, 150, 4601–4609. [PubMed: 8482849]
- El Gaamouch F, Jing P, Xia J, & Cai D (2016). Alzheimer's Disease Risk Genes and Lipid Regulators. *J Alzheimers Dis*, 53, 15–29. [PubMed: 27128373]
- Emoto N, & Yanagisawa M (1995). Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. *J Biol Chem*, 270, 15262–15268. [PubMed: 7797512]
- Esiri MM (2007). The interplay between inflammation and neurodegeneration in CNS disease. *J Neuroimmunol*, 184, 4–16. [PubMed: 17187866]
- Fauci AS (1996). Host factors and the pathogenesis of HIV-induced disease. *Nature*, 384, 529–534. [PubMed: 8955267]
- Fecteau MH, Honore JC, Plante M, Labonte J, Rae GA, & D'Orleans-Juste P (2005). Endothelin-1 (1–31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. *Hypertension*, 46, 87–92. [PubMed: 15956117]
- Feldstein C, & Romero C (2007). Role of endothelins in hypertension. *Am J Ther*, 14, 147–153. [PubMed: 17414582]
- Fernandez-Garcia MD, Mazzon M, Jacobs M, & Amara A (2009). Pathogenesis of flavivirus infections: using and abusing the host cell. *Cell Host Microbe*, 5, 318–328. [PubMed: 19380111]
- Figueras-Aloy J, Gómez L, Rodríguez-Miguélez JM, Jordán Y, Salvia MD, Jiménez W, & Carbonell-Estrany X (2003). Plasma nitrite/nitrate and endothelin-1 concentrations in neonatal sepsis. *Acta Pædiatrica*, 92, 582–587.

- Figueras-Aloy J, Gómez-Lopez L, Rodríguez-Miguélez JM, Jordán-García Y, Salvia-Roiges MD, Jiménez W, & Carbonell-Estrany X (2004). Plasma endothelin-1 and clinical manifestations of neonatal sepsis. *J Perinat Med*, 32, 522–526. [PubMed: 15576275]
- Fitzpatrick ME, Nouraie M, Gingo MR, Camp D, Kessinger CJ, Sincebaugh JB, Clarke A, Ries JW, Klerup EC, Kingsley L, & Morris A (2016). Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. *AIDS*, 30, 1327–1339. [PubMed: 26990629]
- Flores-Chavez M, Faez Y, Olalla JM, Cruz I, Garate T, Rodriguez M, Blanc P, & Canavate C (2008). Fatal congenital Chagas' disease in a non-endemic area: a case report. *Cases J*, 1, 302. [PubMed: 18992159]
- Freeman BD, Machado FS, Tanowitz HB, & Desruisseaux MS (2014). Endothelin-1 and its role in the pathogenesis of infectious diseases. *Life Sci*, 118, 110–119. [PubMed: 24780317]
- Freeman BD, Martins YC, Akide-Ndunge OB, Bruno FP, Wang H, Tanowitz HB, Spray DC, & Desruisseaux MS (2016). Endothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria. *PLoS Pathog*, 12, e1005477. [PubMed: 27031954]
- Furr SR, & Marriott I (2012). Viral CNS infections: role of glial pattern recognition receptors in neuroinflammation. *Front Microbiol*, 3, 201. [PubMed: 22723794]
- Gao HX, Campbell SR, Cui MH, Zong P, Hee-Hwang J, Gulinello M, Putterman C (2009). Depression is an early disease manifestation in lupus-prone MRL/lpr mice. *J Neuroimmunol*, 207, 45–56. [PubMed: 19121871]
- Garkowski A, Zajkowska J, Zajkowska A, Kulakowska A, Zajkowska O, Kubas B, Jurgilewicz D, Hladunski M, & Lebkowska U (2017). Cerebrovascular Manifestations of Lyme Neuroborreliosis-A Systematic Review of Published Cases. *Front Neurol*, 8, 146. [PubMed: 28473801]
- Giaid A, Gibson SJ, Herrero MT, Gentleman S, Legon S, Yanagisawa M, Masaki T, Ibrahim NB, Roberts GW, Rossi ML, & et al. (1991). Topographical localisation of endothelin mRNA and peptide immunoreactivity in neurones of the human brain. *Histochemistry*, 95, 303–314. [PubMed: 2050550]
- Giuliani D, Ottani A, Mioni C, Bazzani C, Galantucci M, Minutoli L, Bitto A, Zaffe D, Botticelli AR, Squadrito F, & Guarini S (2007). Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. *Eur J Pharmacol*, 570, 57–65. [PubMed: 17588564]
- Gonzalez-Perez MP, Peters PJ, O'Connell O, Silva N, Harbison C, Cummings Macri S, Kaliyaperumal S, Luzuriaga K, & Clapham PR (2017). Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications. *J Virol*, 91.
- Gorin FA, Bale JF, Jr., Halks-Miller M, & Schwartz RA (1985). Kaposi's sarcoma metastatic to the CNS. *Arch Neurol*, 42, 162–165. [PubMed: 3977646]
- Goto T, Hussein MH, Kato S, Daoud GA, Kato T, Sugiura T, Kakita H, Nobata M, Kamei M, Mizuno H, Imai M, Ito T, Kato I, Suzuki S, Okada N, Togari H, & Okada H (2012). Endothelin receptor antagonist attenuates oxidative stress in a neonatal sepsis piglet model. *Pediatr Res*, 72, 600–605. [PubMed: 23041664]
- Gould EA, & Solomon T (2008). Pathogenic flaviviruses. *Lancet*, 371, 500–509. [PubMed: 18262042]
- Grab DJ, Chakravorty SJ, van der Heyde H, & Stins MF (2011). How can microbial interactions with the blood-brain barrier modulate astroglial and neuronal function? *Cell Microbiol*, 13, 1470–1478. [PubMed: 21824246]
- Gramolelli S, & Ojala PM (2017). Kaposi's sarcoma herpesvirus-induced endothelial cell reprogramming supports viral persistence and contributes to Kaposi's sarcoma tumorigenesis. *Curr Opin Virol*, 26, 156–162. [PubMed: 29031103]
- Grant WB, Campbell A, Itzhaki RF, & Savory J (2002). The significance of environmental factors in the etiology of Alzheimer's disease. *J Alzheimers Dis*, 4, 179–189. [PubMed: 12226537]
- Grimwood K, Anderson VA, Bond L, Catroppa C, Hore RL, Keir EH, Nolan T, & Robertson DM (1995). Adverse outcomes of bacterial meningitis in school-age survivors. *Pediatrics*, 95, 646–656. [PubMed: 7536915]

- Grimwood K, Anderson P, Anderson V, Tan L, & Nolan T (2000). Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. *Archives of Disease in Childhood*, 83, 111–116. [PubMed: 10906014]
- Gu J, Pinheiro CZ, Yu Z, D'Andrea M, Murlidharan S, & Malik A (1991). The biosynthesis of endothelin-like immunoreactivity in epithelium and fibroblasts of the human umbilical cord. *Tissue Cell*, 23, 437–444. [PubMed: 1926136]
- Guabiraba R, & Ryffel B (2014). Dengue virus infection: current concepts in immune mechanisms and lessons from murine models. *Immunology*, 141, 143–156. [PubMed: 24182427]
- Guerriero F, Sgarlata C, Francis M, Maurizi N, Faragli A, Perna S, Rondanelli M, Rollone M, & Ricevuti G (2016). Neuroinflammation, immune system and Alzheimer disease: searching for the missing link. *Aging Clin Exp Res*, 29, 821–831. [PubMed: 27718173]
- Gulinello M, & Putterman C (2011). The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus. *J Biomed Biotechnol*, 2011, 207504. [PubMed: 21331367]
- Gulinello M, Wen J, & Putterman C (2012). Neuropsychiatric Symptoms in Lupus. *Psychiatr Ann*, 42, 322–328. [PubMed: 25620816]
- Guo L, Li M, Chen Y, Wang Q, Tian Z, Pan S, Zeng X, & Ye S (2015). Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. *Arthritis Rheumatol*, 67, 2394–2402. [PubMed: 26018988]
- Guo Y, Chung SK, Siu CW, Kwan SC, Ho PW, Yeung PK, & Chan KH (2014). Endothelin-1 overexpression exacerbate experimental allergic encephalomyelitis. *J Neuroimmunol*, 276, 64–70. [PubMed: 25205217]
- Halstead SB (2002). Dengue. *Curr Opin Infect Dis*, 15, 471–476. [PubMed: 12686878]
- Hammond TR, Gadea A, Dupree J, Kerninon C, Nait-Oumesmar B, Aguirre A, & Gallo V (2014). Astrocyte-Derived Endothelin-1 Inhibits Remyelination through Notch Activation. *Neuron*, 81, 1442.
- Hammond TR, McEllin B, Morton PD, Raymond M, Dupree J, & Gallo V (2015). Endothelin-B Receptor Activation in Astrocytes Regulates the Rate of Oligodendrocyte Regeneration during Remyelination. *Cell Rep*, 13, 2090–2097. [PubMed: 26628380]
- Hanaoka T, Kimura N, Aso Y, Takemaru M, Kimura Y, Ishibashi M, & Matsubara E (2016). Relationship between white matter lesions and regional cerebral blood flow changes during longitudinal follow up in Alzheimer's disease. *Geriatr Gerontol Int*, 16, 836–842. [PubMed: 26245516]
- Hanson GC, Andersson KE, Gyllstedt E, Hogestatt ED, & Lindberg BF (1997). Hydrolysis of big endothelin-1 by a serine protease in the membrane fraction of human lung. *Regul Pept*, 68, 63–69. [PubMed: 9094756]
- Harris SA, & Harris EA (2015). Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease. *J Alzheimers Dis*, 48, 319–353. [PubMed: 26401998]
- Hasegawa H, Hiki K, Sawamura T, Aoyama T, Okamoto Y, Miwa S, Shimohama S, Kimura J, & Masaki T (1998). Purification of a novel endothelin-converting enzyme specific for big endothelin-3. *FEBS Lett*, 428, 304–308. [PubMed: 9654154]
- Haufschild T, Shaw SG, Kesselring J, & Flammer J (2001). Increased endothelin-1 plasma levels in patients with multiple sclerosis. *J Neuroophthalmol*, 21, 37–38. [PubMed: 11315981]
- Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C, & Group H (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol*, 17, 3–16. [PubMed: 21174240]
- Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, & Dugas TR (2004). Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. *Cardiovasc Toxicol*, 4, 117–131. [PubMed: 15371629]
- Helset E, Sildnes T, & Konopski ZS (1994). Endothelin-1 Stimulates Monocytes in vitro to Release Chemotactic Activity Identified as Interleukin-8 and Monocyte Chemotactic Protein-1. *Mediators Inflamm*, 3, 155–160. [PubMed: 18472935]

- Hendarto SK, & Hadinegoro SR (1992). Dengue encephalopathy. *Acta Paediatr Jpn*, 34, 350–357. [PubMed: 1509881]
- Hioki Y, Okada K, Ito H, Matsuyama K, & Yano M (1991). Endothelin converting enzyme of bovine carotid artery smooth muscles. *Biochem Biophys Res Commun*, 174, 446–451. [PubMed: 1899566]
- Hisaki K, Matsumura Y, Nishiguchi S, Fujita K, Takaoka M, & Morimoto S (1993). Endothelium-independent pressor effect of big endothelin-1 and its inhibition by phosphoramidon in rat mesenteric artery. *Eur J Pharmacol*, 241, 75–81. [PubMed: 8223929]
- Hofman FM, Chen P, Jeyaseelan R, Incardona F, Fisher M, & Zidovetzki R (1998). Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. *Blood*, 92, 3064–3072. [PubMed: 9787140]
- Hong S, & Banks WA (2015). Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. *Brain Behav Immun*, 45, 1–12. [PubMed: 25449672]
- Hostenbach S, D'Haeseleer M, Kooijman R, & De Keyser J (2016). The pathophysiological role of astrocytic endothelin-1. *Prog Neurobiol*, 144, 88–102. [PubMed: 27132521]
- Hou J, Baker LA, Zhou L, & Klein RS (2016). Viral interactions with the blood-brain barrier: old dog, new tricks. *Tissue Barriers*, 4, e1142492. [PubMed: 27141421]
- Huang MB, Hunter M, & Bond VC (1999). Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. *AIDS Res Hum Retroviruses*, 15, 1265–1277. [PubMed: 10505675]
- Huang YJ, Higgs S, Horne KM, & Vanlandingham DL (2014). Flavivirus-mosquito interactions. *Viruses*, 6, 4703–4730. [PubMed: 25421894]
- Hunt NH, & Grau GE (2003). Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. *Trends Immunol*, 24, 491–499. [PubMed: 12967673]
- Idro R, Marsh K, John CC, & Newton CR (2010). Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. *Pediatr Res*, 68, 267–274. [PubMed: 20606600]
- Iglarz M, & Clozel M (2007). Mechanisms of ET-1-induced endothelial dysfunction. *J Cardiovasc Pharmacol*, 50, 621–628. [PubMed: 18091577]
- Imaizumi T, Nishizaka S, Ayabe M, Shoji H, Ichiyama T, & Sugita Y (2005). Probable chronic viral encephalitis with microglial nodules in the entire brain: a case report with necropsy. *Med Sci Monit*, 11, CS23–26. [PubMed: 15874892]
- Ishikawa N, Takemura M, Koyama Y, Shigenaga Y, Okada T, & Baba A (1997). Endothelins promote the activation of astrocytes in rat neostriatum through ET(B) receptors. *Eur J Neurosci*, 9, 895–901. [PubMed: 9182942]
- Ishizawa K, Yoshizumi M, Tsuchiya K, Houchi H, Minakuchi K, Izawa Y, Kanematsu Y, Kagami S, Hirose M, & Tamaki T (2004). Dual effects of endothelin-1 (1–31): induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells. *Hypertens Res*, 27, 433–440. [PubMed: 15253109]
- Jellinger KA, Setinek U, Drlicek M, Bohm G, Steurer A, & Lintner F (2000). Neuropathology and general autopsy findings in AIDS during the last years. *Acta Neuropathol*, 100, 213–220. [PubMed: 10963370]
- Jeong S (2017). Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease. *Mol Cells*, 40, 613–620. [PubMed: 28927263]
- Jhan MK, Tsai TT, Chen CL, Tsai CC, Cheng YL, Lee YC, Ko CY, Lin YS, Chang CP, Lin LT, & Lin CF (2017). Dengue virus infection increases microglial cell migration. *Sci Rep*, 7, 91. [PubMed: 28273893]
- Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, & Fyhrquist F (1991). Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. *Ann Rheum Dis*, 50, 526–527.
- Kahn HJ, Bailey D, & Marks A (2002). Monoclonal antibody D2–40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. *Mod Pathol*, 15, 434–440. [PubMed: 11950918]
- Kang BY, Kleinhenz JM, Murphy TC, & Hart CM (2011). The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. *Am J Physiol Lung Cell Mol Physiol*, 301, L881–891. [PubMed: 21926265]

- Kang T, Ye FC, Gao SJ, & Wang LD (2008). Angiogenesis, Kaposi's Sarcoma and Kaposi's Sarcoma-Associated Herpesvirus. *Virol Sin*, 23, 449–458. [PubMed: 19890492]
- Kanmogne GD, Kennedy RC, & Grammas P (2001). Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. *AIDS Res Hum Retroviruses*, 17, 45–53. [PubMed: 11177382]
- Kanmogne GD, Primeaux C, & Grammas P (2005). Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. *Biochem Biophys Res Commun*, 333, 1107–1115. [PubMed: 15979050]
- Karim S, Mirza Z, Kamal MA, Abuzenadah AM, Azhar EI, Al-Qahtani MH, Damanhoury GA, Ahmad F, Gan SH, & Sohrab SS (2014). The role of viruses in neurodegenerative and neurobehavioral diseases. *CNS Neurol Disord Drug Targets*, 13, 1213–1223. [PubMed: 25230220]
- Kaul M, Garden GA, & Lipton SA (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature*, 410, 988–994. [PubMed: 11309629]
- Kaul M, Zheng J, Okamoto S, Gendelman HE, & Lipton SA (2005). HIV-1 infection and AIDS: consequences for the central nervous system. *Cell Death Differ*, 12 Suppl 1, 878–892. [PubMed: 15832177]
- Kedzierski RM, & Yanagisawa M (2001). Endothelin system: the double-edged sword in health and disease. *Annu Rev Pharmacol Toxicol*, 41, 851–876. [PubMed: 11264479]
- Kennan RP, Machado FS, Lee SC, Desruisseaux MS, Wittner M, Tsuji M, & Tanowitz HB (2005). Reduced cerebral blood flow and N-acetyl aspartate in a murine model of cerebral malaria. *Parasitol Res*, 96, 302–307. [PubMed: 15918069]
- Khimji AK, & Rockey DC (2010). Endothelin--biology and disease. *Cell Signal*, 22, 1615–1625. [PubMed: 20466059]
- Kiely PD, Pecht I, & Oliveira DB (1997). Mercuric chloride-induced vasculitis in the Brown Norway rat: alpha beta T cell-dependent and - independent phases: role of the mast cell. *J Immunol*, 159, 5100–5106. [PubMed: 9366439]
- Kim KS (2010). Acute bacterial meningitis in infants and children. *Lancet Infect Dis*, 10, 32–42. [PubMed: 20129147]
- Kimura N, Nakama H, Nakamura K, Aso Y, & Kumamoto T (2012). Effect of white matter lesions on brain perfusion in Alzheimer's disease. *Dement Geriatr Cogn Disord*, 34, 256–261. [PubMed: 23183589]
- Kimura T, Sasaki M, Okumura M, Kim E, & Sawa H (2010). Flavivirus encephalitis: pathological aspects of mouse and other animal models. *Vet Pathol*, 47, 806–818. [PubMed: 20551474]
- Kirkitadze MD, & Kowalska A (2005). Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. *Acta Biochim Pol*, 52, 417–423. [PubMed: 15933761]
- Klohs J, Rudin M, Shimshek DR, & Beckmann N (2014). Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. *Front Aging Neurosci*, 6, 32. [PubMed: 24659966]
- Kobayashi T, Oku H, Fukuhara M, Kojima S, Komori A, Ichikawa M, Katsumura K, Kobayashi M, Sugiyama T, & Ikeda T (2005). Endothelin-1 enhances glutamate-induced retinal cell death, possibly through ETA receptors. *Invest Ophthalmol Vis Sci*, 46, 4684–4690. [PubMed: 16303965]
- Koberle F (1968). Chagas' disease and Chagas' syndromes: the pathology of American trypanosomiasis. *Adv Parasitol*, 6, 63–116. [PubMed: 4239747]
- Koedel U, Gorris C, Lorenz S, & Pfister HW (1997). Increased endothelin levels in cerebrospinal fluid samples from adults with bacterial meningitis. *Clinical Infectious Diseases*, 25, 329–330. [PubMed: 9332538]
- Koedel U, Lorenz S, Gorris C, Arendt RM, & Pfister HW (1998). Endothelin B receptor-mediated increase of cerebral blood flow in experimental pneumococcal meningitis. *Journal of Cerebral Blood Flow and Metabolism*, 18, 67–74. [PubMed: 9428307]
- Kohan DE, Rossi NF, Inscho EW, & Pollock DM (2011). Regulation of blood pressure and salt homeostasis by endothelin. *Physiol Rev*, 91, 1–77. [PubMed: 21248162]
- Korth P, Bohle RM, Corvol P, & Pinet F (1999). Cellular distribution of endothelin-converting enzyme-1 in human tissues. *J Histochem Cytochem*, 47, 447–462. [PubMed: 10082746]

- Koyama Y, Baba A, & Matsuda T (2007). Production of monocyte chemoattractant protein-1 and cytokine-induced neutrophil chemoattractant-1 in rat brain is stimulated by intracerebroventricular administration of an endothelin ETB receptor agonist. *Neuroreport*, 18, 1275–1279. [PubMed: 17632282]
- Koyama Y, Kotani M, Sawamura T, Kuribayashi M, Konishi R, & Michinaga S (2013). Different actions of endothelin-1 on chemokine production in rat cultured astrocytes: reduction of CX3CL1/fractalkine and an increase in CCL2/MCP-1 and CXCL1/CINC-1. *J Neuroinflammation*, 10, 51. [PubMed: 23627909]
- Koyuncu OO, Hogue IB, & Enquist LW (2013). Virus infections in the nervous system. *Cell Host Microbe*, 13, 379–393. [PubMed: 23601101]
- Kuwaki T, Ling GY, Onodera M, Ishii T, Nakamura A, Ju KH, Cao WH, Kumada M, Kurihara H, Kurihara Y, Yazaki Y, Ohuchi T, Yanagisawa M, & Fukuda Y (1999). Endothelin in the central control of cardiovascular and respiratory functions. *Clin Exp Pharmacol Physiol*, 26, 989–994. [PubMed: 10626068]
- Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, Helbok R, Tannich E, & Schmutzhard E (2006). Behavioural and histopathological alterations in mice with cerebral malaria. *Neuropathol Appl Neurobiol*, 32, 177–188. [PubMed: 16599946]
- Lacosta AM, Insua D, Badi H, Pesini P, & Sarasa M (2017). Neurofibrillary Tangles of Abeta₄₀ in Alzheimer's Disease Brains. *J Alzheimers Dis*, 58, 661–667. [PubMed: 28453491]
- Lake EMR, Bazzigaluppi P, Mester J, Thomason LAM, Janik R, Brown M, McLaurin J, Carlen PL, Corbett D, Stanis GJ, & Stefanovic B (2017). Neurovascular unit remodelling in the subacute stage of stroke recovery. *Neuroimage*, 146, 869–882. [PubMed: 27664828]
- Lane JH, Sasseville VG, Smith MO, Vogel P, Pauley DR, Heyes MP, Lackner AA (1996). Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. *J Neurovirol*, 2, 423–432. [PubMed: 8972425]
- Lannes N, Summerfield A, & Filgueira L (2017). Regulation of inflammation in Japanese encephalitis. *J Neuroinflammation*, 14, 158. [PubMed: 28807053]
- Lannuzel A, Lledo PM, Lamghitnia HO, Vincent JD, & Tardieu M (1995). HIV-1 envelope proteins gp120 and gp160 potentiate NMDA-induced [Ca²⁺]_i increase, alter [Ca²⁺]_i homeostasis and induce neurotoxicity in human embryonic neurons. *Eur J Neurosci*, 7, 2285–2293. [PubMed: 8563977]
- Lee ME, de la Monte SM, Ng SC, Bloch KD, & Quertermous T (1990). Expression of the potent vasoconstrictor endothelin in the human central nervous system. *J Clin Invest*, 86, 141–147. [PubMed: 2195059]
- Leib SL, Kim YS, Chow LL, Sheldon RA, & Tauber MG (1996). Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. *Journal of Clinical Investigation*, 98, 2632–2639. [PubMed: 8958228]
- Letendre S (2011). Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. *Top Antivir Med*, 19, 137–142. [PubMed: 22156215]
- Leung JW, Ho MC, Lo AC, Chung SS, & Chung SK (2004). Endothelial cell-specific over-expression of endothelin-1 leads to more severe cerebral damage following transient middle cerebral artery occlusion. *J Cardiovasc Pharmacol*, 44 Suppl 1, S293–300. [PubMed: 15838304]
- Levy RM, Pons VG, & Rosenblum ML (1984). Central nervous system mass lesions in the acquired immunodeficiency syndrome (AIDS). *J Neurosurg*, 61, 9–16. [PubMed: 6610028]
- Li GH, Ning ZJ, Liu YM, & Li XH (2017). Neurological Manifestations of Dengue Infection. *Front Cell Infect Microbiol*, 7, 449. [PubMed: 29119088]
- Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S, & Elton TS (1994). Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. *J Appl Physiol* (1985), 77, 1451–1459. [PubMed: 7836152]
- Li H, Li Y, Wen B, Zhang J, Wang C, Song Z, Li S, Qu X, Huang R, & Liu W (2017). Dengue virus and Japanese encephalitis virus infection of the central nervous system share similar profiles of

cytokine accumulation in cerebrospinal fluid. *Cent Eur J Immunol*, 42, 218–222. [PubMed: 28860941]

Lindenbach BD, & Rice CM (2003). Molecular biology of flaviviruses. *Adv Virus Res*, 59, 23–61. [PubMed: 14696326]

Lipitsa T, Naukkarinen A, & Harvima IT (2015). Mast cell tryptase and chymase in the progress of cutaneous vasculitis. *Arch Dermatol Res*, 307, 917–924. [PubMed: 26498154]

Love S, & Miners JS (2016). Cerebrovascular disease in ageing and Alzheimer's disease. *Acta Neuropathol*, 131, 645–658. [PubMed: 26711459]

Lum FM, Low DK, Fan Y, Tan JJ, Lee B, Chan JK, Renia L, Ginhoux F, & Ng LF (2017). Zika Virus Infects Human Fetal Brain Microglia and Induces Inflammation. *Clin Infect Dis*, 64, 914–920. [PubMed: 28362944]

Luo J, & Grammas P (2010). Endothelin-1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective. *J Alzheimers Dis*, 21, 887–896. [PubMed: 20634595]

Ma KC, Nie XJ, Hoog A, Olsson Y, & Zhang WW (1994). Reactive astrocytes in viral infections of the human brain express endothelin-like immunoreactivity. *J Neurol Sci*, 126, 184–192. [PubMed: 7531760]

Machado FS, Desruisseaux MS, Nagajyothi, Kennan RP, Hetherington HP, Wittner M, Weiss LM, Lee SC, Scherer PE, Tsuji M, & Tanowitz HB (2006). Endothelin in a murine model of cerebral malaria. *Exp Biol Med (Maywood)*, 231, 1176–1181. [PubMed: 16741072]

Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, & Nath A (1995). Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. *Ann Neurol*, 37, 373–380. [PubMed: 7695237]

Malik S, & Eugenin EA (2016). Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication Systems. *Curr HIV Res*, 14, 400–411. [PubMed: 27009098]

Mangone CA, Sica RE, Pereyra S, Genovese O, Segura E, Riarte A, Sanz OP, & Segura M (1994). Cognitive impairment in human chronic Chagas' disease. *Arquivos de Neuro-Psiquiatria*, 52, 200–203. [PubMed: 7826247]

Marasciulo FL, Montagnani M, & Potenza MA (2006). Endothelin-1: the yin and yang on vascular function. *Curr Med Chem*, 13, 1655–1665. [PubMed: 16787211]

Marques CP, Hu S, Sheng W, & Lokensgard JR (2006). Microglial cells initiate vigorous yet non-protective immune responses during HSV-1 brain infection. *Virus Res*, 121, 1–10. [PubMed: 16621100]

Martino G, Poliani PL, Furlan R, Marconi P, Glorioso JC, Adorini L, & Comi G (2000). Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. *J Neuroimmunol*, 107, 184–190. [PubMed: 10854655]

Martins YC, Freeman BD, Akide Ndunge OB, Weiss LM, Tanowitz HB, & Desruisseaux MS (2016). Endothelin-1 Treatment Induces an Experimental Cerebral Malaria-Like Syndrome in C57BL/6 Mice Infected with Plasmodium berghei NK65. *Am J Pathol*, 186, 2957–2969. [PubMed: 27640146]

Masaki T (2004). Historical review: Endothelin. *Trends Pharmacol Sci*, 25, 219–224. [PubMed: 15063086]

Masocha W, & Kristensson K (2012). Passage of parasites across the blood-brain barrier. *Virulence*, 3, 202–212. [PubMed: 22460639]

Matsumoto H, Suzuki N, Onda H, & Fujino M (1989). Abundance of endothelin-3 in rat intestine, pituitary gland and brain. *Biochem Biophys Res Commun*, 164, 74–80. [PubMed: 2508641]

Matsuo Y, Mihara S, Ninomiya M, & Fujimoto M (2001). Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. *Stroke*, 32, 2143–2148. [PubMed: 11546909]

Matsushima H, Yamada N, Matsue H, & Shimada S (2004). The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. *Eur J Immunol*, 34, 1910–1919. [PubMed: 15214039]

Matsuura S, Ikegaya Y, Yamada MK, Nishiyama N, & Matsuki N (2002). Endothelin downregulates the glutamate transporter GLAST in cAMP-differentiated astrocytes in vitro. *Glia*, 37, 178–182. [PubMed: 11754215]

- Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, & Bateman RJ (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science*, 330, 1774. [PubMed: 21148344]
- McArthur JC (2004). HIV dementia: an evolving disease. *J Neuroimmunol*, 157, 3–10. [PubMed: 15579274]
- McCarron RM, Wang L, Stanimirovic DB, & Spatz M (1993). Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. *Neurosci Lett*, 156, 31–34. [PubMed: 7692362]
- McGavern DB, & Kang SS (2011). Illuminating viral infections in the nervous system. *Nat Rev Immunol*, 11, 318–329. [PubMed: 21508982]
- McMahon EG, Palomo MA, Moore WM, McDonald JF, & Stern MK (1991). Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1–39) in vivo and conversion of big endothelin-1-(1–39) to endothelin-1-(1- in vitro. *Proc Natl Acad Sci U S A*, 88, 703–707. [PubMed: 1992461]
- Mendoza Ticona CA, Cordova Benzaquen E, Ancca Juarez J, Saldana Diaz J, Torres Choque A, Velasquez Talavera R, de los Rios Alvarez J, Vega Chirinos S, & Sanchez Perez R (2005). [The prevalence of Chagas' disease in puerperal women and congenital transmission in an endemic area of Peru]. *Rev Panam Salud Publica*, 17, 147–153. [PubMed: 15826393]
- Merkelbach S, Sittlinger H, Schweizer I, & Muller M (2000). Cognitive outcome after bacterial meningitis. *Acta Neurologica Scandinavica*, 102, 118–123. [PubMed: 10949529]
- Meyding-Lamade U, & Strank C (2012). Herpesvirus infections of the central nervous system in immunocompromised patients. *Ther Adv Neurol Disord*, 5, 279–296. [PubMed: 22973424]
- Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi G, Winter DR, Cuda CM, & Putterman C (2018). Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. *Frontiers in Immunology*, In Press.
- Miller RD, Monsul NT, Vender JR, & Lehmann JC (1996). NMDA- and endothelin-1-induced increases in blood-brain barrier permeability quantitated with Lucifer yellow. *J Neurol Sci*, 136, 37–40. [PubMed: 8815176]
- Minami M, Kimura M, Iwamoto N, & Arai H (1995). Endothelin-1-like immunoreactivity in cerebral cortex of Alzheimer-type dementia. *Prog Neuropsychopharmacol Biol Psychiatry*, 19, 509–513. [PubMed: 7624501]
- Miner JJ, & Diamond MS (2016). Mechanisms of restriction of viral neuroinvasion at the blood-brain barrier. *Curr Opin Immunol*, 38, 18–23. [PubMed: 26590675]
- Miyasaka N, Hirata Y, Ando K, Sato K, Morita H, Shichiri M, Kanno K, Tomita K, & Marumo F (1992). Increased production of endothelin-1 in patients with inflammatory arthritides. *Arthritis Rheum*, 35, 397–400. [PubMed: 1567488]
- Montagne A, Zhao Z, & Zlokovic BV (2017). Alzheimer's disease: A matter of blood-brain barrier dysfunction? *J Exp Med*, 214, 3151–3169. [PubMed: 29061693]
- Mortara RA, da Silva S, Patricio FR, Higuchi ML, Lopes ER, Gabbai AA, Carnevale P, Rocha A, Ferreira MS, Souza MM, de Franco MF, Turcato G, Jr., & Ferraz Neto BH (1999). Imaging *Trypanosoma cruzi* within tissues from chagasic patients using confocal microscopy with monoclonal antibodies. *Parasitol Res*, 85, 800–808. [PubMed: 10494805]
- Mossakowski MJ, & Zelman IB (1997). Neuropathological syndromes in the course of full blown acquired immune deficiency syndrome (AIDS) in adults in Poland (1987–1995). *Folia Neuropathol*, 35, 133–143. [PubMed: 9595847]
- Motte S, McEntee K, & Naeije R (2006). Endothelin receptor antagonists. *Pharmacol Ther*, 110, 386–414. [PubMed: 16219361]
- Munawwar A, & Singh S (2016). Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression. *J Lab Physicians*, 8, 5–18. [PubMed: 27013807]
- Murphy BR, & Whitehead SS (2011). Immune response to dengue virus and prospects for a vaccine. *Annu Rev Immunol*, 29, 587–619. [PubMed: 21219187]
- Murphy MP, & LeVine H, 3rd. (2010). Alzheimer's disease and the amyloid-beta peptide. *J Alzheimers Dis*, 19, 311–323. [PubMed: 20061647]

- Myers BD, Kessler E, Levi J, Pick A, Rosenfeld JB, & Tikvah P (1974). Kaposi sarcoma in kidney transplant recipients. *Arch Intern Med*, 133, 307–311. [PubMed: 4591269]
- Naidoo V, Naidoo S, Mahabeer R, & Raidoo DM (2004). Cellular distribution of the endothelin system in the human brain. *J Chem Neuroanat*, 27, 87–98. [PubMed: 15121213]
- Naidoo V, Naidoo S, & Raidoo DM (2004). Immunolocalisation of endothelin-1 in human brain. *J Chem Neuroanat*, 27, 193–200. [PubMed: 15183204]
- Nakamura T, Ebihara I, Tomino Y, & Koide H (1995). Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. *Kidney Int*, 47, 481–489. [PubMed: 7723234]
- Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, & Kido H (1997). Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. *J Immunol*, 159, 1987–1992. [PubMed: 9257865]
- Naldi L, Venturuzzo A, & Invernizzi P (2018). Dermatological Complications After Solid Organ Transplantation. *Clin Rev Allergy Immunol*, 54, 185–212. [PubMed: 29177692]
- Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I, Ohno N, & Nakashima T (2003). Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. *Pharmacology and Toxicology*, 92, 21–26. [PubMed: 12710593]
- Nascimento CR, Andrade D, Carvalho-Pinto CE, Serra RR, Vellasco L, Brasil G, Ramos-Junior ES, da Mota JB, Almeida LN, Andrade MV, Correia Soeiro MN, Juliano L, Alvarenga PH, Oliveira AC, Sicuro FL, de Carvalho ACC, Svensjo E, & Scharfstein J (2017). Mast Cell Coupling to the Kallikrein-Kinin System Fuels Intracardiac Parasitism and Worsens Heart Pathology in Experimental Chagas Disease. *Front Immunol*, 8, 840. [PubMed: 28824610]
- Newton CR, & Krishna S (1998). Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. *Pharmacol Ther*, 79, 1–53. [PubMed: 9719344]
- Nisimura LM, Estado V, de Souza EM, Reis PA, Lessa MA, Castro-Faria-Neto HC, Pereira MC, Tibirica E, & Garzoni LR (2014). Acute chagas disease induces cerebral microvasculopathy in mice. *PLoS Negl Trop Dis*, 8, e2998. [PubMed: 25010691]
- Norberg P (2010). Divergence and genotyping of human alpha-herpesviruses: an overview. *Infect Genet Evol*, 10, 14–25. [PubMed: 19772930]
- Oliveira-Filho J, Vieira-de-Melo RM, Reis PS, Lacerda AM, Neville IS, Cincura C, Menezes DF, Viana LC, Jesus PA, Lopes AA, Reis FJ, & Furie KL (2009). Chagas disease is independently associated with brain atrophy. *J Neurol*, 256, 1363–1365. [PubMed: 19363636]
- Onwujekwe O, Chima R, & Okonkwo P (2000). Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holo-endemic Nigerian communities. *Health Policy*, 54, 143–159. [PubMed: 11094267]
- Orsini F, De Blasio D, Zangari R, Zanier ER, & De Simoni MG (2014). Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. *Front Cell Neurosci*, 8, 380. [PubMed: 25426028]
- Pacheco-Quinto J, & Eckman EA (2013). Endothelin-converting enzymes degrade intracellular beta-amyloid produced within the endosomal/lysosomal pathway and autophagosomes. *J Biol Chem*, 288, 5606–5615. [PubMed: 23283972]
- Pacheco-Quinto J, Herdt A, Eckman CB, & Eckman EA (2013). Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. *J Alzheimers Dis*, 33 Suppl 1, S101–110. [PubMed: 22903130]
- Palmer JC, Baig S, Kehoe PG, & Love S (2009). Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. *Am J Pathol*, 175, 262–270. [PubMed: 19541930]
- Palmer JC, & Love S (2011). Endothelin receptor antagonists: potential in Alzheimer's disease. *Pharmacol Res*, 63, 525–531. [PubMed: 21193044]
- Palmer JC, Barker R, Kehoe PG, & Love S (2012). Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-beta. *J Alzheimers Dis*, 29, 853–861. [PubMed: 22330820]
- Palmer JC, Tayler HM, & Love S (2013). Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease. *J Alzheimers Dis*, 36, 577–587. [PubMed: 23629587]

- Pantanowitz L, & Dezube BJ (2008). Kaposi sarcoma in unusual locations. *BMC Cancer*, 8, 190. [PubMed: 18605999]
- Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, & Mullan M (2003). Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. *Neurol Res*, 25, 642–651. [PubMed: 14503019]
- Patel CA, Mukhtar M, & Pomerantz RJ (2000). Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. *J Virol*, 74, 9717–9726. [PubMed: 11000244]
- Pentreath VW (1995). Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 19 May 1994. Trypanosomiasis and the nervous system. *Pathology and immunology. Trans R Soc Trop Med Hyg*, 89, 9–15. [PubMed: 7747319]
- Perry D, Sang A, Yin Y, Zheng YY, & Morel L (2011). Murine models of systemic lupus erythematosus. *J Biomed Biotechnol*, 2011, 271694. [PubMed: 21403825]
- Perry VH, & Teeling J (2013). Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. *Semin Immunopathol*, 35, 601–612. [PubMed: 23732506]
- Petkova SB, Tanowitz HB, Magazine HI, Factor SM, Chan J, Pestell RG, Bouzahzah B, Douglas SA, Shtutin V, Morris SA, Tsang E, Weiss LM, Christ GJ, Wittner M, & Huang H (2000). Myocardial expression of endothelin-1 in murine *Trypanosoma cruzi* infection. *Cardiovasc Pathol*, 9, 257–265. [PubMed: 11064272]
- Petkova SB, Huang H, Factor SM, Pestell RG, Bouzahzah B, Jelicks LA, Weiss LM, Douglas SA, Wittner M, & Tanowitz HB (2001). The role of endothelin in the pathogenesis of Chagas' disease. *International Journal for Parasitology*, 31, 499–511. [PubMed: 11334935]
- Petrov T, Steiner J, Braun B, & Rafols JA (2002). Sources of endothelin-1 in hippocampus and cortex following traumatic brain injury. *Neuroscience*, 115, 275–283. [PubMed: 12401340]
- Pfister LA, Tureen JH, Shaw S, Christen S, Ferriero DM, Tauber MG, Leib SL (2000). Endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis. *Annals of Neurology*, 47, 329–335. [PubMed: 10716252]
- Piechota M, Banach M, Irzmanski R, Barylski M, Piechota-Urbanska M, Kowalski J, & Pawlicki L (2007). Plasma endothelin-1 levels in septic patients. *Journal of Intensive Care Medicine*, 22, 232–239. [PubMed: 17722367]
- Pittella JE (2009). Central nervous system involvement in Chagas disease: a hundred-year-old history. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 103, 973–978. [PubMed: 19457529]
- Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, Lozano E, Alba MA, Segarra M, Espigol-Frigole G, Prieto-Gonzalez S, Hernandez-Rodriguez J, Preciado S, Lavilla R, & Cid MC (2017). Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. *Ann Rheum Dis*, 76, 1624–1634. [PubMed: 28606962]
- Post MJ, Sheldon JJ, Hensley GT, Soila K, Tobias JA, Chan JC, Quencer RM, & Moskowitz LB (1986). Central nervous system disease in acquired immunodeficiency syndrome: prospective correlation using CT, MR imaging, and pathologic studies. *Radiology*, 158, 141–148. [PubMed: 3940372]
- Potchen MJ, Birbeck GL, Demarco JK, Kampondeni SD, Beare N, Molyneux ME, & Taylor TE (2010). Neuroimaging findings in children with retinopathy-confirmed cerebral malaria. *European Journal of Radiology*, 74, 262–268. [PubMed: 19345538]
- Prado CM, Jelicks LA, Weiss LM, Factor SM, Tanowitz HB, & Rossi MA (2011). The vasculature in chagas disease. *Advances in Parasitology*, 76, 83–99. [PubMed: 21884888]
- Purushothaman P, Uppal T, Sarkar R, & Verma SC (2016). KSHV-Mediated Angiogenesis in Tumor Progression. *Viruses*, 8.
- Py MO (2011). Neurologic manifestations of Chagas disease. *Curr Neurol Neurosci Rep*, 11, 536–542. [PubMed: 21904918]
- Ramesh G, MacLean AG, & Philipp MT (2013). Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. *Mediators Inflamm*, 2013, 480739. [PubMed: 23997430]

- Ransohoff RM, & Perry VH (2009). Microglial physiology: unique stimuli, specialized responses. *Annu Rev Immunol*, 27, 119–145. [PubMed: 19302036]
- Ransohoff RM, & Brown MA (2012). Innate immunity in the central nervous system. *J Clin Invest*, 122, 1164–1171. [PubMed: 22466658]
- Rassi A, Jr., Rassi A, & Marcondes de Rezende J (2012). American trypanosomiasis (Chagas disease). *Infectious Disease Clinics of North America*, 26, 275–291. [PubMed: 22632639]
- Regent A, Ly KH, Groh M, Khifer C, Lofek S, Clary G, Chafey P, Baud V, Broussard C, Federici C, Labrousse F, Mesturoux L, Le Jeune C, Vidal E, Brezin A, Witko-Sarsat V, Guillevin L, & Mouthon L (2017). Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. *Autoimmun Rev*, 16, 398–406. [PubMed: 28232168]
- Reijerkerk A, Lakeman KA, Drexhage JA, van Het Hof B, van Wijck Y, van der Pol SM, Kooij G, Geerts D, & de Vries HE (2012). Brain endothelial barrier passage by monocytes is controlled by the endothelin system. *Journal of Neurochemistry*, 121, 730–737. [PubMed: 21777246]
- Renia L, Wu Howland S, Claser C, Charlotte Gruner A, Suwanarusk R, Hui Teo T, Russell B, & Ng L (2012). Cerebral malaria: Mysteries at the blood-brain barrier. *Virulence*, 3.
- Rivest S (2009). Regulation of innate immune responses in the brain. *Nat Rev Immunol*, 9, 429–439. [PubMed: 19461673]
- Roach T, & Alcendor DJ (2017). Zika virus infection of cellular components of the blood-retinal barriers: implications for viral associated congenital ocular disease. *J Neuroinflammation*, 14, 43. [PubMed: 28253931]
- Roca C, Pinazo MJ, López-Chejade P, Bayó J, Posada E, López-Solana J, Gállego M, Portús M, & J. G (2011). Chagas disease among the Latin American adult population attending in a primary care center in Barcelona, Spain. *PLoS Negl Trop Dis*, 5, e1135. [PubMed: 21572511]
- Rolinski B, Heigermoser A, Lederer E, Bogner JR, Loch O, & Goebel FD (1999). Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy. *Infection*, 27, 244–247. [PubMed: 10885834]
- Rosano L, Spinella F, Di Castro V, Nicotra MR, Albin A, Natali PG, & Bagnato A (2003). Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. *Am J Pathol*, 163, 753–762. [PubMed: 12875994]
- Rubanyi GM, & Polokoff MA (1994). Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. *Pharmacol Rev*, 46, 325–415. [PubMed: 7831383]
- Rwomushana RJ, Bailey IC, & Kyalwazi SK (1975). Kaposi's sarcoma of the brain. A case report with necropsy findings. *Cancer*, 36, 1127–1131. [PubMed: 1182666]
- Sacktor N, Tarwater PM, Skolasky RL, McArthur JC, Selnes OA, Becker J, Cohen B, Miller EN, & Multicenter for ACS (2001). CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. *Neurology*, 57, 542–544. [PubMed: 11502933]
- Sacktor N (2002). The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. *J Neurovirol*, 8 Suppl 2, 115–121. [PubMed: 12491162]
- Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, & Mahmoudi J (2015). Amyloid-beta: a crucial factor in Alzheimer's disease. *Med Princ Pract*, 24, 1–10.
- Saez-Llorens X, & McCracken GH, Jr. (2003). Bacterial meningitis in children. *Lancet*, 361, 2139–2148. [PubMed: 12826449]
- Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, & Masaki T (1990). Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. *Nature*, 348, 732–735. [PubMed: 2175397]
- Salvador F, Treviño B, Sulleiro E, Pou D, Sánchez-Montalvá A, Cabezas J, Soriano A, Serre N, Gómez IPJ, Pahissa A, & Molina I (2013). Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile. *Clin Microbiol Infect*
- Salvarani C, Brown RD, Jr., Christianson T, Miller DV, Giannini C, Huston J, 3rd, & Hunder GG (2015). An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis: description of patients. *Medicine (Baltimore)*, 94, e738. [PubMed: 26020379]

- Samransamruajkit R, Moonviriyakit K, Vanapongtipagorn P, Prapphal N, Deerojanawong J, & Poovorawan Y (2002). Plasma endothelin-1 in infants and young children with acute bronchiolitis and viral pneumonia. *Asian Pac J Allergy Immunol*, 20, 229–234. [PubMed: 12744623]
- Scheglovitova ON, Romanov YA, Maksianina EV, Svintsitskaya VA, & Pronin AG (2002). Herpes simplex type I virus infected human vascular endothelial cells induce the production of anti-viral and proinflammatory factors by peripheral blood leukocytes in vitro. *Russ J Immunol*, 7, 115–122. [PubMed: 12687253]
- Scheglovitova ON, Skliankina NN, Boldyreva NV, Babayants AA, & Frolova IS (2013). Effect of type 1 herpes simplex infection of phenotypic peculiarities of human vascular endothelial cells in culture. *Bull Exp Biol Med*, 155, 151–158. [PubMed: 23667894]
- Schinelli S (2002). The brain endothelin system as potential target for brain-related pathologies. *Current Drug Targets CNS Neurological Disorders*, 1, 543–553. [PubMed: 12769596]
- Schinelli S (2006). Pharmacology and physiopathology of the brain endothelin system: an overview. *Curr Med Chem*, 13, 627–638. [PubMed: 16529555]
- Schuetz P, Stolz D, Mueller B, Morgenthaler NG, Struck J, Mueller C, Bingisser R, Tamm M, & Christ-Crain M (2008). Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. *BMC Infect Dis*, 8, 22. [PubMed: 18304365]
- Schwartz A, Schlaak J, Lotz J, Pfers I, Meyer zum Buschenfelde KH, & Mayet WJ (1996). Endothelin-1 modulates the expression of adhesion molecules on fibroblast-like synovial cells (FLS). *Scandinavian Journal of Rheumatology*, 25, 246–256. [PubMed: 8792802]
- Schwartz M, & Deczkowska A (2016). Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. *Trends Immunol*, 37, 668–679. [PubMed: 27616557]
- Scutari R, Alteri C, Perno CF, Svicher V, & Aquaro S (2017). The Role of HIV Infection in Neurologic Injury. *Brain Sci*, 7.
- Sellner J, Tauber MG, & Leib SL (2010). Pathogenesis and pathophysiology of bacterial CNS infections. *Handb Clin Neurol*, 96, 1–16. [PubMed: 20109671]
- Serrano-Pozo A, Frosch MP, Masliah E, & Hyman BT (2011). Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med*, 1, a006189. [PubMed: 22229116]
- Sessa WC, Kaw S, Hecker M, & Vane JR (1991). The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. *Biochem Biophys Res Commun*, 174, 613–618. [PubMed: 1993057]
- Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, & Mohan G (2017). Neuroinflammation pathways: a general review. *Int J Neurosci*, 127, 624–633. [PubMed: 27412492]
- Shimada K, Takahashi M, & Tanzawa K (1994). Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. *J Biol Chem*, 269, 18275–18278. [PubMed: 8034569]
- Silva AA, Roffe E, Marino AP, dos Santos PV, Quirico-Santos T, Paiva CN, & Lannes-Vieira J (1999). Chagas' disease encephalitis: intense CD8+ lymphocytic infiltrate is restricted to the acute phase, but is not related to the presence of *Trypanosoma cruzi* antigens. *Clin Immunol*, 92, 56–66. [PubMed: 10413653]
- Silva N, O'Bryan L, Medeiros E, Holand H, Suleiman J, de Mendonca JS, Patronas N, Reed SG, Klein HG, Masur H, & Badaro R (1999). *Trypanosoma cruzi* Meningoencephalitis in HIV-Infected Patients. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 20, 342–349.
- Silverman AJ, Sutherland AK, Wilhelm M, & Silver R (2000). Mast cells migrate from blood to brain. *J Neurosci*, 20, 401–408. [PubMed: 10627616]
- Simmons CP, Farrar JJ, Nguyen v V, & Wills B (2012). Dengue. *N Engl J Med*, 366, 1423–1432. [PubMed: 22494122]
- Singhi S, Kissoon N, & Bansal A (2007). Dengue and dengue hemorrhagic fever: management issues in an intensive care unit. *J Pediatr (Rio J)*, 83, S22–35. [PubMed: 17530136]
- Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, & Shepherd CE (2009). Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. *Brain Pathol*, 19, 392–398. [PubMed: 18637012]

- Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, Loan HT, Day NP, Farrar J, Myint KS, Warrell MJ, James WS, Nisalak A, & White NJ (2000). Neurological manifestations of dengue infection. *Lancet*, 355, 1053–1059. [PubMed: 10744091]
- Speciale L, Roda K, Saresella M, Taramelli D, & Ferrante P (1998). Different endothelins stimulate cytokine production by peritoneal macrophages and microglial cell line. *Immunology*, 93, 109–114. [PubMed: 9536126]
- Speciale L, Biffi R, Mancuso R, Borghi E, Mazziotti R, & Ferrante P (2006). Big endothelin-1 and interleukin-6 modulation in human microvascular endothelial cells after human herpesvirus 8 infection. *Exp Biol Med (Maywood)*, 231, 1171–1175. [PubMed: 16741071]
- Sprenger H, Rosler A, Tonn P, Braune HJ, Huffmann G, & Gemsa D (1996). Chemokines in the cerebrospinal fluid of patients with meningitis. *Clinical Immunology and Immunopathology*, 80, 155–161. [PubMed: 8764560]
- Springer JM, Raveendran VV, Gierer SA, Maz M, & Dileepan KN (2017). Protective Role of Mast Cells in Primary Systemic Vasculitis: A Perspective. *Front Immunol*, 8, 990. [PubMed: 28878769]
- Stankowska DL, Krishnamoorthy VR, Ellis DZ, & Krishnamoorthy RR (2017). Neuroprotective effects of curcumin on endothelin-1 mediated cell death in hippocampal neurons. *Nutr Neurosci*, 20, 273–283. [PubMed: 26651837]
- Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, Heffner RR, Jr. (1997). Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. *J Neuropathol Exp Neurol*, 56, 435–439. [PubMed: 9100674]
- Stock AD, Wen J, Doerner J, Herlitz LC, Gulinello M, & Putterman C (2015). Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice. *J Neuroinflammation*, 12, 205. [PubMed: 26546449]
- Strazza M, Pirrone V, Wigdahl B, & Nonnemacher MR (2011). Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. *Brain Res*, 1399, 96–115. [PubMed: 21641584]
- Struck J, Morgenthaler NG, & Bergmann A (2005). Proteolytic processing pattern of the endothelin-1 precursor in vivo. *Peptides*, 26, 2482–2486. [PubMed: 15978702]
- Sugimoto K, Nakazato K, Sato A, Suzuki S, Yoshihisa A, Machida T, Saitoh SI, Sekine H, & Takeishi Y (2017). Autoimmune disease mouse model exhibits pulmonary arterial hypertension. *PLoS One*, 12, e0184990. [PubMed: 28926602]
- Sun X, Chen WD, & Wang YD (2015). beta-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. *Front Pharmacol*, 6, 221. [PubMed: 26483691]
- Swanson PA, 2nd, & McGavern DB (2015). Viral diseases of the central nervous system. *Curr Opin Virol*, 11, 44–54. [PubMed: 25681709]
- Swindells S, Zheng J, & Gendelman HE (1999). HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions. *AIDS Patient Care STDS*, 13, 153–163. [PubMed: 10375263]
- Takahashi K, Ghatei MA, Jones PM, Murphy JK, Lam HC, O'Halloran DJ, & Bloom SR (1991). Endothelin in human brain and pituitary gland: comparison with rat. *J Cardiovasc Pharmacol*, 17 Suppl 7, S101–103.
- Takahashi M, Fukuda K, Shimada K, Barnes K, Turner AJ, Ikeda M, Koike H, Yamamoto Y, & Tanzawa K (1995). Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. *Biochem J*, 311 (Pt 2), 657–665. [PubMed: 7487910]
- Tan IL, & McArthur JC (2012). HIV-associated neurological disorders: a guide to pharmacotherapy. *CNS Drugs*, 26, 123–134. [PubMed: 22201342]
- Tanowitz HB, Burns ER, Sinha AK, Kahn NN, Morris SA, Factor SM, Hatcher VB, Bilezikian JP, Baum SG, & Wittner M (1990). Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. *Am J Trop Med Hyg*, 43, 274–281. [PubMed: 2121055]
- Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, & Wittner M (1992). Chagas' disease. *Clin Microbiol Rev*, 5, 400–419. [PubMed: 1423218]

- Tanowitz HB, Kaul DK, Chen B, Morris SA, Factor SM, Weiss LM, Wittner M (1996). Compromised microcirculation in acute murine *Trypanosoma cruzi* infection. *Journal of Parasitology*, 82, 124–130. [PubMed: 8627481]
- Tanowitz HB, Huang H, Jelicks LA, Chandra M, Lored ML, Weiss LM, Factor SM, Shtutin V, Mukherjee S, Kitsis RN, Christ GJ, Wittner M, Shirani J, Kisanuki YY, & Yanagisawa M (2005). Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. *Infect Immun*, 73, 2496–2503. [PubMed: 15784596]
- Tanowitz HB, Weiss LM, & Montgomery SP (2011). Chagas disease has now gone global. *PLoS Negl Trop Dis*, 5, e1136. [PubMed: 21572510]
- Tanzi RE, & Bertram L (2001). New frontiers in Alzheimer's disease genetics. *Neuron*, 32, 181–184. [PubMed: 11683989]
- Tchougounova E, Pejler G, & Abrink M (2003). The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. *J Exp Med*, 198, 423–431. [PubMed: 12900518]
- Teder P, & Noble PW (2000). A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. *Am J Respir Cell Mol Biol*, 23, 7–10. [PubMed: 10873147]
- Thomas EA, John M, & Kanish B (2010). Mucocutaneous manifestations of Dengue fever. *Indian J Dermatol*, 55, 79–85. [PubMed: 20418984]
- Thomas T, Miners S, & Love S (2015). Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer's disease and vascular dementia. *Brain*, 138, 1059–1069. [PubMed: 25688080]
- Tol J, Roks G, Slooter AJ, & van Duijn CM (1999). Genetic and environmental factors in Alzheimer's disease. *Rev Neurol (Paris)*, 155 Suppl 4, S10–16. [PubMed: 10637933]
- Torres M, & Villalça J (1919). Encefalite e mielite causadas por um Tripanozomo. *Memorias do Instituto Oswaldo Cruz*, 11, 80–89.
- Trillo-Pazos G, Diamanturos A, Rislove L, Menza T, Chao W, Belem P, Sadiq S, Morgello S, Sharer L, & Volsky DJ (2003). Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. *Brain Pathol*, 13, 144–154. [PubMed: 12744468]
- Tsai TT, Chen CL, Lin YS, Chang CP, Tsai CC, Cheng YL, Huang CC, Ho CJ, Lee YC, Lin LT, Jhan MK, & Lin CF (2016). Microglia retard dengue virus-induced acute viral encephalitis. *Sci Rep*, 6, 27670. [PubMed: 27279150]
- Tschaikowsky K, Sagner S, Lehnert N, Kaul M, & Ritter J (2000). Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. *Crit Care Med*, 28, 1854–1860. [PubMed: 10890632]
- Tsukahara H, Ende H, Magazine HI, Bahou WF, & Goligorsky MS (1994). Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. *J Biol Chem*, 269, 21778–21785. [PubMed: 7520443]
- Ubhi K, & Masliah E (2013). Alzheimer's disease: recent advances and future perspectives. *J Alzheimers Dis*, 33 Suppl 1, S185–194. [PubMed: 22810100]
- van de Weg CA, Pannuti CS, van den Ham HJ, de Araujo ES, Boas LS, Felix AC, Carvalho KI, Levi JE, Romano CM, Centrone CC, Rodrigues CL, Luna E, van Gorp EC, Osterhaus AD, Kallas EG, & Martina BE (2014). Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers for plasma leakage in patients with acute dengue virus infection. *J Clin Virol*, 60, 328–335. [PubMed: 24928471]
- Varvel NH, Neher JJ, Bosch A, Wang W, Ransohoff RM, Miller RJ, Dingledine R (2016). Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus. *Proc Natl Acad Sci U S A*, 113, E5665–5674. [PubMed: 27601660]
- Verma R, Sahu R, & Holla V (2014). Neurological manifestations of dengue infection: a review. *J Neurol Sci*, 346, 26–34. [PubMed: 25220113]
- Vianna G (1911). Contribuição para o estudo da anatomia patológica da “Molestia de Carlos Chagas”: Esquizotripanose humana ou tireoidite parasitária. *Memorias do Instituto Oswaldo Cruz*, 3, 276–292.

- Vilaseca J, Arnau JM, Bacardi R, Mieras C, Serrano A, & Navarro C (1982). Kaposi's sarcoma and toxoplasma gondii brain abscess in a Spanish homosexual. *Lancet*, 1, 572.
- Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, & Binder BR (1992). Polar secretion of endothelin-1 by cultured endothelial cells. *J Biol Chem*, 267, 16066–16068. [PubMed: 1644793]
- Wallace JL, Cirino G, De Nucci G, McKnight W, & MacNaughton WK (1989). Endothelin has potent ulcerogenic and vasoconstrictor actions in the stomach. *Am J Physiol*, 256, G661–666. [PubMed: 2650567]
- Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, & Fassbender K (2007). Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. *Cell Physiol Biochem*, 20, 947–956. [PubMed: 17982277]
- Wanecek M, Weitzberg E, Rudehill A, & Oldner A (2000). The endothelin system in septic and endotoxin shock. *Eur J Pharmacol*, 407, 1–15. [PubMed: 11050285]
- Wang DB, Dayton RD, Zweig RM, & Klein RL (2010). Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response. *Exp Neurol*, 224, 197–206. [PubMed: 20346943]
- Wang LK, Hong Z, Wu GF, & Li C (2013). Perihematomal endothelin-1 level is associated with an increase in blood-brain barrier permeability in a rabbit model of intracerebral hematoma. *Chinese Medical Journal*, 126, 3433–3438. [PubMed: 24034085]
- Wang S, Wang R, Chen L, Bennett DA, Dickson DW, & Wang DS (2010). Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. *J Neurochem*, 115, 47–57. [PubMed: 20663017]
- Weitzberg E, Lundberg JM, & Rudehill A (1991). Elevated plasma levels of endothelin in patients with sepsis syndrome. *Circ Shock*, 33, 222–227. [PubMed: 2065442]
- Welch K, Finkbeiner W, Alpers CE, Blumenfeld W, Davis RL, Smuckler EA, & Beckstead JH (1984). Autopsy findings in the acquired immune deficiency syndrome. *JAMA*, 252, 1152–1159. [PubMed: 6471338]
- Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, & Putterman C (2013). Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. *J Autoimmun*, 43, 44–54. [PubMed: 23578591]
- Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Sturzl M, Kerjaschki D, Alitalo K, & Tschachler E (1999). Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. *Lab Invest*, 79, 243–251. [PubMed: 10068212]
- Wenisch C, Wenisch H, Wilairatana P, Looareesuwan S, Vannaphan S, Wagner O, Graninger W, Schonthal E, & Rumpold H (1996). Big endothelin in patients with complicated *Plasmodium falciparum* malaria. *J Infect Dis*, 173, 1281–1284. [PubMed: 8627087]
- Werner C, & Engelhard K (2007). Pathophysiology of traumatic brain injury. *Br J Anaesth*, 99, 4–9. [PubMed: 17573392]
- World Health Organization. (2014). Severe Malaria. *Tropical Medicine & International Health*, 19, 7–131. [PubMed: 25214480]
- World Health Organization. (2017). World Malaria Report 2017. In (Vol. 2017).
- Xanthos DN, & Sandkuhler J (2014). Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. *Nat Rev Neurosci*, 15, 43–53. [PubMed: 24281245]
- Xie A, Gao J, Xu L, & Meng D (2014). Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. *Biomed Res Int*, 2014, 648740. [PubMed: 24900975]
- Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, & Yanagisawa M (1994). ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. *Cell*, 78, 473–485. [PubMed: 8062389]
- Yaiw KC, Mohammad AA, Costa H, Taher C, Badrnya S, Assinger A, Wilhelmi V, Ananthaseshan S, Estekizadeh A, Davoudi B, Ovchinnikova O, Shlyakhto E, Rafnsson A, Khan Z, Butler L, Rahbar A, Pernow J, & Soderberg-Naucleer C (2015). Human Cytomegalovirus Up-Regulates Endothelin Receptor Type B: Implication for Vasculopathies? *Open Forum Infect Dis*, 2, ofv155.

- Yamada H, & Kurokawa K (1998). Histochemical studies on endothelin and the endothelin-A receptor in the hypothalamus. *J Cardiovasc Pharmacol*, 31 Suppl 1, S215–218. [PubMed: 9595441]
- Yamamoto T, & Uemura H (1998). Distribution of endothelin-B receptor-like immunoreactivity in rat brain, kidney, and pancreas. *J Cardiovasc Pharmacol*, Suppl 1, S207–211. [PubMed: 9595439]
- Yamashita K, Discher DJ, Hu J, Bishopric NH, & Webster KA (2001). Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. *J Biol Chem*, 276, 12645–12653. [PubMed: 11278891]
- Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, & Yanagisawa M (2000). Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. *J Clin Invest*, 105, 1373–1382. [PubMed: 10811845]
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, & Masaki T (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*, 332, 411–415. [PubMed: 2451132]
- Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, & Kano S (1995). Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. *Ann Rheum Dis*, 54, 361–365. [PubMed: 7794041]
- Yoshizawa T, Shinmi O, Giaid A, Yanagisawa M, Gibson SJ, Kimura S, Uchiyama Y, Polak JM, Masaki T, & Kanazawa I (1990). Endothelin: a novel peptide in the posterior pituitary system. *Science*, 247, 462–464. [PubMed: 2405487]
- Younger DS (2004). Vasculitis of the nervous system. *Curr Opin Neurol*, 17, 317–336. [PubMed: 15167068]
- Zayyad Z, & Spudich S (2015). Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). *Curr HIV/AIDS Rep*, 12, 16–24. [PubMed: 25604237]
- Zhang WW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie JX, Olsson Y, & Sourander P (1994). Structural and vasoactive factors influencing intracerebral arterioles in cases of vascular dementia and other cerebrovascular disease: a review. Immunohistochemical studies on expression of collagens, basal lamina components and endothelin-1. *Dementia*, 5, 153–162. [PubMed: 8087171]
- Zhang X, Yeung PK, McAlonan GM, Chung SS, & Chung SK (2013). Transgenic mice over-expressing endothelial endothelin-1 show cognitive deficit with blood-brain barrier breakdown after transient ischemia with long-term reperfusion. *Neurobiol Learn Mem*, 101, 46–54. [PubMed: 23313614]
- Zhou L, Miranda-Saksena M, & Saksena NK (2013). Viruses and neurodegeneration. *Virol J*, 10, 172. [PubMed: 23724961]
- Zidovetzki R, Chen P, Chen M, & Hofman FM (1999). Endothelin-1-induced interleukin-8 production in human brain-derived endothelial cells is mediated by the protein kinase C and protein tyrosine kinase pathways. *Blood*, 94, 1291–1299. [PubMed: 10438717]

Figure 1

Figure 1: ET-1 and cell-cell interactions in Central Nervous System diseases.

(A) In the sub-endothelial matrix (top of the figure), the biologically inactive precursor big-ET-1 (1–38) is cleaved by mast cell derived chymase, yielding ET-1 (1–31) which is subsequently released into the circulation where it is enzymatically-activated to ET-1 via the membrane bound neutral endopeptidase. As the major circulatory enzyme involved in the generation of ET-1, the endothelin converting enzyme (ECE) directly converts the 38-amino acid precursor to ET-1). Within the vessel lumen, the later peptide signals via two distinct G protein coupled receptors, namely ET_A and/or ET_B (not shown). In response to insults to the

endothelium, ET-1 can induce remodeling of endothelial cells, with an increase in adhesion molecule production, and loss of BBB integrity. **(B)** After endothelial insults, ET-1 also increases the expression of chemokines such as CCL2 from endothelial cells and triggers the release of monocyte-derived CXCL8, resulting in margination of inflammatory cells and diapedesis across the BBB. Macrophages are well known to convert big-ET-1 to ET-1 and can secrete several cytokines such as interleukin-1 and TNF α , chemokines, including CCL2 and CCL5, reactive oxygen species, and ET-1 once differentiated within the CNS. ET-1 can also prompt astrocyte activation and proliferation and subsequent activation of microglial cells, resulting in reactive microgliosis. In neurons, ET-1 via its two receptors may act as a modulator of neuronal conductivity and/or neurotransmission.